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1 The Institute – an Overview 
The Ludwig Boltzmann Institute for Health Technology Assessment (LBI-
HTA) was formally founded on March 2006 and is intended to operate for a 
period of seven years. Therefore 2010 was the 5th year of the institute’s opera-
tional activity. Evaluation regarding its continuation until 2013 took place in 
spring 2009. The evaluation results were (fortunately) very positive. 
In 2010 the annual budget of the Ludwig Boltzmann Institute for Health 
Technology Assessment - funded by the Ludwig Boltzmann Society and in-
stitutional partners – was € 820.000. Additional third party funding 
amounted to 12.4% of the budget. 
1.1 Partners 
In line with the research policy of the Ludwig Boltzmann Society, the insti-
tute focuses on translational research. The research programme requires 
strong emphasis on applicable short term or medium term results. By setting 
up partnerships between research-producing and research-applying organisa-
tions or institutions, the quick transfer of research results is guaranteed. 
The partner-institutions of the Ludwig Boltzmann Institute for Health 
Technology Assessment are stakeholders in health care administration (2), 
responsible bodies of public hospitals (2) and private universities (1).  
 
TILAK/ Tiroler Landeskrankenanstalten GmbH 
Anichstraße 35, 6020 Innsbruck 
http://www.tilak.at 
KAGES/ Steiermärkische Krankenanstalten GmbH 
Stiftingtalstraße 4-6, 8010 Graz 
http://www.kages.at 
 
2010:  
5th year of existence 
evaluation regarding 
continuation until 2013 
total budget 
institutional partners 
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AUVA/ Allgemeine Unfallversicherungsanstalt 
Adalbert-Stifterstraße 65, 1201 Wien  
http://www.auva.at 
(until May 2010) 
BMG/ Bundesministerium für Gesundheit  
Radetzkystraße 2, 1030 Wien  
http://www.bmg.gv.at 
UMIT/ Private Universität für Gesundheitswissenschaften, Medi-
zinische Informatik und Technik 
Institut für Public Health, Medical Decision Making und HTA 
Eduard Wallnöfer-Zentrum I, 6060 Hall  
http://www.umit.at 
PMU/ Paracelsus Medizinische Privatuniversität 
Institut für Public Health  
Ignaz Harrer Straße 79, 5020 Salzburg 
http://www.pmu.ac.at 
(until May 2010) 
HVB/ Hauptverband der österreichischen Sozialversicherungsträger  
Kundmanngasse 21, 1030 Wien 
http://www.hauptverband.at 
(since 2008) 
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1.2 Committees 
The LBI-HTA is supported by two committees, namely the Board of Trus-
tees and the Scientific Advisory Group (SAG). 
Figure 1.3-1: Organigramm 
Whereas the LBI-HTA’s research programme provides a general methodo-
logical background, agenda setting for current projects is the task of the 
Board of Trustees, which is composed of one representative from each insti-
tutional partner. 
 
KAGES: Mag. Dr. August Gomsi (Chair) 
TILAK: Univ. Prof. Dr. Wolfgang Buchberger 
BMG: Dr. Wolfgang Ecker resp. Dr. Silvia Türk 
UMIT: Univ. Prof. Dr. Uwe Siebert 
LBG: Mag. Claudia Lingner  
HVB: Dr. Gottfried Endel 
Board meetings 2010: 
 1st Board meeting: 23/03/2010 
 2nd Board meeting: 12/10/2010 
6 board members 
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The first board meeting in 2010 dealt with the issues of contract extensions 
with partners, budget and current academic program, and the topic of identi-
fication and prioritization of the work program for 2010 to 2012. 
The second board meeting in 2010 included reports from the Director and 
the Deputy as well as much discussion with and input from the Board. The 
following topics were discussed: 
 Budget 2010/11 
 Current scientific  programm 2010/11  
 Scoping und defining issues content: centralized care in oncology. 
 The future of the Institute - 2013+: Presentation of LBI-HTA pro-
jects and its results: „Impact of HTA-research on the Austrian 
health care system” followed by a presentation of possible models 
for the maintenance and sustainable implementation of the Insti-
tute in Austria. 
The Scientific Advisory Group (SAG) gives scientific support and is se-
lected – with equal weighting – by the Ludwig Boltzmann Society and the 
members of the Board of Trustees. The SAG is composed of the following 
members: 
 Univ. Prof. Dr. Finn Borlum Kristensen/ DK (Chair) 
 Univ. Prof. Dr. Alistair Gray/ UK 
 Univ. Prof. Dr. Jürgen Windeler/ D 
 Dr. Dagmar Lühman/ D 
 Dr. Irina Cleemput/ BE (since 2010) 
Following a four year of contribution, Univ. Prof. Norman Waugh/ UK left 
the academic Board of LBI-HTA in 2010. His successor is Dr. Irina Cleem-
put from the Belgian Health Care Knowledge Center/ KCE. 
The fourth meeting of the Scientific Advisory Group took place at the LBI-
HTA on 23/11/2010. 
The morning began with the Institute’s Director’s breif brief summary of the 
results of the Evaluation in May 2009 and the research conducted in the sub-
sequent year. Then four employees presented individual projects perceived to 
be particularly methodologically challenging. The aims of the Scientific Ad-
visory Board meeting were to obtain expert opinions and, where necessary, 
suggestions for improvement and to explore potential cooperation opportuni-
ties. Projects in the field of health services research are particularly challeng-
ing:  
 Outpatient cardiac rehabilitation: Retrospective cohort study 
(with/ without phase III rehabilitation) and, as a follow-up project 
in 2010/11, development of a study protocol for a prospective, con-
trolled study to assess the effectiveness of phase III rehabilitation 
(Brigitte Piso) 
 Observational study of kypho- and vertebroplasty (Brigitte Piso) 
 Evaluations of child and adolescent psychiatry (Roman Winkler) 
1st board meeting 
23/03/2010 
 
2nd board meeting  
12/10/2010 
5 members of the 
Scientific Advisory 
Group 
4thmeeting of the 
Scientific Advisory 
Group:  
23/11/2010 
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 Measuring disease – Patient-relevant outcomes versus surrogate 
outcomes – an international manual? (Anna Nachtnebel) 
The afternoon was devoted to the future of LBI-HTA (2013+). First, the Di-
rector, Claudia Wild, presented the research profile and excerpts from the 
previously-developed strategy. This was followed by report from the Insti-
tute’s Deputy, Ingrid Zechmeister on the results of the recent LBI-HTA pro-
ject „ The impact of HTA on the health care system in Austria“. By means of 
a discussion, the meeting’s participants tried to identify the structural and 
procedural requirements for the LBI-HTA to become an independent HTA 
Institute in the future.  
1.3 Staff & Human Resources Development 
As an interdisciplinary institute the organisation of work is guided by profes-
sional – assigned topic-specific – project management. Again, the compulsory 
weekly team meeting (Tuesdays at 2 p.m.) proved to be essential and neces-
sary for effective team communication at the LBI-HTA. 
Director & Head of department ‘High Tech in Hospitals’: 
 Claudia Wild, Priv.-Doz. Dr. phil. 
Research Background: Communication Science, Psychology, Politi-
cal Science, Social Medicine 
Deputy Director & Head of department ‘Health Economics’: 
 Ingrid Zechmeister, Dr. rer. soc. oec., MA 
Research Background: Health Economics 
Head of department ‘Public Health & Health Services Research’: 
 Brigitte Piso, Dr. med., MPH 
Research Background: Medicine, Public Health  
Office-Assistant: 
 Smiljana Blagojevic, Dipl.-Ing.  
Background: Agronomy 
Assistant-to-the-director & Science Communications: 
 Gerda Hinterreiter, Mag. rer. soc. oec.  
Research Background: Medical Sociology, Communication  
Information Specialist: 
  Tarquin Mittermayr, BA (Hons) 
Senior Researchers: 
 Roman Winkler, Dr. phil, MSc  
Research Background: Communication Science 
 Anna Nachtnebel, Dr. med., MSc PH 
Research Background: Medicine, Public Health 
 Stefan Mathis, Dr. med., Dipl.-Ing.  
 Research Background: Medicine, Biomedical Informatics 
 
organisation of work 
team members  
currently (Dec 2010)  
15 persons in total 
 (=13 FTE) 
 
and many cooperative 
research partners 
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 Marisa Warmuth, Dr. med., MIPH 
Research Background: Medicine, Public Health 
 Philipp Radlberger, Mag. rer. soc. oec.  
Research Background: Health Economics 
 Katharina Hintringer, BA 
Research Background: Social- and Health Management 
 Philipp Mad, Dr. med. 
Wissenschaftsdisziplin: Medicine 
 Ines Schumacher, MPH (freelance research stuff) 
Research Background: Public Health 
 Nikolaus Patera, Mag. rer. soc. oec. (freelance research stuff) 
Research Background: Health policy/ health services research 
 Sabine Geiger-Gritsch, Mag. pharm., Dr. scient.med. (until 30/09/2010) 
Research Background: Pharmacy, Public Health 
 Tim Johansson, Mag. phil., MSc (until  31/05/2010) 
Research Background: Public Health 
 Michael Gyimesi, Dr. tech. Dipl.-Ing. (until 30.06.2010) 
Research Background: Modelling, Simulation  
Junior Researcher: 
 Muna Abuzahra, BCS  
Research Background: Health Management 
Layout & Graphic Design: 
 Darko Blagojevic 
Trainees:  
 Imke Schall, Bakk (01/08/2010 – 30/09/2010) 
Research Background: Health Management 
 Matthias Ristl (31/07/2010 – 31/08/2010) 
 Student 
Literature Acquisition : 
 Johannes Setz 
 Laura Brückner 
 Thomas Stumpner 
Furthermore, there are also external experts working on several projects for 
the LBI-HTA. In 2010 those were: 
 Christopher Adlbrecht, Dr. med. 
Research Background: Medicine 
 Gisela Schott, Dr. med. 
Research Background: Medicine 
 Tina Loibl, BA 
Research Background: Health Management 
 Christoph Obermair, DI Dr. 
Research Background: Computer science 
many assistants 
external experts 
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Personnel who left the LBI-HTA in 2010: 
Tim Johansson worked as a researcher at the LBI-HTA until 31/05/2010, 
working in the field of Public Health (40 hrs. /week); He has since worked at 
the Paracelsus Private Medical University Salzburg. 
Michael Gyimesi worked as a researcher at the LBI-HTA until 30/06/2010. 
At the LBI-HTA he worked in the field of Modelling and Simulation (20 
hrs/week); he has since worked at the Institute for Analysis and Scientific 
Computing at the Technical University of Vienna.  
Sabine Geiger-Gritsch worked as a researcher at the LBI-HTA until 
30/09/2010. She was active in the field of Pharmacy and Health Sciences (20 
hrs./week). Since 01/10/2010 Sabine Geiger-Gritsch has been employed ex-
clusively at the UMIT.  
Besides the organisational development of an interdisciplinary research insti-
tute, professionalisation and specialisation of the team members are key is-
sues. Becoming an interdisciplinary research institute involves the exchange 
of perspectives and methodologies, cooperation during projects, internal 
presentations and discussions and internal evaluations in order to ensure 
high quality work.  
The LBG arranges regular CPD training for the leaders of its institutes, with 
the aim of the professionalisation of its management. Thus Claudia Wild 
completed a training course entitled „Successes and challenges for managers 
– Good Leadership“ at the Kothmuehle Relax Resort in Neuhofen an der 
Ybbs in Lower Austria, which took place from 28th to 30th June 2010.  
All researchers took part in the following methodological training courses: 
 „Performance-oriented hospital financing, documentation and ac-
counting“ LBI-HTA, Vienna (Lecturer: Dr. Christian Rous/ 
KAGes), 15:00 – 17:00, 04/05/2010 
 „Health care data/ Data sources: Health care planning in Austria“, 
LBI-HTA, Vienna (Lecturer: Dr. Gerhard Fülöp/ ÖBIG), 15:00 – 
17:00, 02/06/2010 
 „IVF – successes, failures“, LBI-HTA, Vienna (Lecturer: Univ.-
Doz. DDr. Barbara Maier/ SALK), 16:00-17:30, 01/09/2010 
Several researchers attended the following courses: 
 Round table discussion on „oncology versus economy“, Vienna, 
19/05/2010 (Anna Nachtnebel) 
 Elsevier Librarian-Forum 2010: "New approaches, innovative solu-
tions and enhanced perspectives for academic libraries". Palais Au-
ersperg, Vienna, 19/10/2010 (Tarquin Mittermayr)  
 Training course on “Trials Registers, Trials Results Registers and 
Other Research Registers: Challenges and Opportunities”, Univer-
sity of York/ United Kingdom, 18/11/2010 (Tarquin Mittermayr) 
 “Workshop and winter school on the use of health data, Work group 
collection and use of secondary data” (AGENS), UMIT/ Hall in Ti-
rol, 15-18/03/2010 (Michael Gyimesi) 
 Short course: „How-To-Workshop: Revise and improve your pres-
entation for the meeting“ by M.G.M. Hunink (Netherlands) at the 
change to PMU  
change to TU 
 
only UMIT 
objectives: 
professionalisation, 
specialisation 
methodological training 
specific training for 
some researchers 
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Society for Medical Decision Making 13th European Meeting 2010 
“Public Health Decision Making”, UMIT/ Hall in Tirol, 30/05-
02/06/2010 (Katharina Hintringer) 
 4th Summer School on "Methodological Foundations of Rehabilita-
tion Research", Bielefeld, 02-04/09/2010 (Brigitte Piso) 
 3-Day Certified Course “Modelling approaches for HTA”, UMIT/ 
Hall in Tirol, 27-29/05/2010 (Ingrid Zechmeister) 
 HTA-Workshop on „Pitfalls and misinformation in clinical trials“, 
Gesundheit Österreich GmbH, Vienna, 16-17/12/2010 (Stefan 
Mathis) 
 Pre-Conference-Workshop on „Risk communication between doc-
tors and patients", 11. Annual meeting of the German Network for  
Evidence Based Medicine „EbM – a gain for the doctor-patient re-
lationship?“, Salzburg, 25/02/2010 (Philipp Radlberger) 
Five LBI-HTA staff members (Anna Nachtnebel, Katharina Hintringer, 
Marisa Warmuth, Ines Schumacher and Gerda Hinterreiter) attended the 
„Powertalking – the language of self-conciousness“ seminar given by Mag. 
Christiane Miksch on 08 & 09/11/2010. 
In the summer semester of 2010 Tim Johansson attended the following 
teaching events as part of his postgraduate studies in medical sciences at the 
PMU/ Paracelsus private medical university in Salzburg: “Public Health”, 
“Introduction to Surgery”, “Medical ethics – principles of medical com-
merce” and “Foundation of radiology”. His dissertation was entitled “Tele-
medicine in acute stoke care – the TESSA model”. His final exam will take 
place in January 2011.  
As part of his doctoral studies in the field of economic policy at the Vienna 
University of Economics, Philipp Radlberger attended the following re-
search seminars in the 09/10 and 10/11 winter semesters: „Social policy“, 
„Topics of international trade“ and „Further qualitative methods“.  
Since October 2009 Katharina Hintringer has been a student on the medical 
sciences Masters course at the UMIT (Health and Life Sciences University) 
in Hall in Tirol, with a focus on Public Health. 
The Ludwig Boltzmann Institute for Health Technology Assessment, its 
staff, is a member of the following international and national organisations: 
 HTAi (Health Technology Assessment international) 
 INAHTA (International Network of Health Technology Assess-
ment) 
 EUPHA (European Public Health Association) 
 DNEbM (German Network for Evidence-based Medicine) 
 Society for the Promotion of Technology Assesment in Health Care 
(Health Technology Assessment)  
 ÖGPH (Austrian Society for Public Health) 
 EuroScan (International Information Network on New and Emerg-
ing Health Technologies) 
 EUnetHTA (European network for Health Technology Assessment) 
 „Powertalking –  
the language of  
self-conciousness“ 
university education: 
 
1 doctorate in final 
stages 
1 doctorate ongoing 
1 masters ongoing 
institutional 
memberships 
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Claudia Wild is a member of:  
 OSR/ Supreme Medical Council (Meetings on 26/06/2010 and 
27/11/2010) 
 Project advisory group of the EBM Working Group of the Associa-
tion of Austrian social security companies   
 Scientific Advisory Committee of DAHTA@DIMDI (Meetings on 
26/05 und 10/11/2010)  
 International Advisory Boards of the Magazine for Evidence, Con-
tinuing Education and Quality in Health Care (ZEFQ) 
 Transparency International, Austrian Chapter, Workgroup Health 
Care 
 Advisory Board „ Health Statistics“ by Statistic Austria 
 Expert group of OECD  
 Promotion of research advisory board for German Cancer Aid (char-
ity) 
Further to this, Claudia Wild carried out the following scientific advisory ac-
tivities in 2010:  
 Development of a model for the European Forum for Evidence 
Based Prevention (EUFEP), in cooperation with the Danube Uni-
versity Krems, Department for evidence based medicine and clini-
cal epidemiology, 27/01/2010 
 Participation in the „Caesarean Section“ round table at the Federal 
Ministry of Health, 26/01/2010 
 Participation in the „Quality standards in early breast cancer diag-
nosis“ working group, Gesundheit Österreich GmbH, 12/01/2010 
In 2010, as part of the „child health dialogue“ Ingrid Zechmeister took part 
in the „Health Promotion“ working group (29/06/2010 and 16/11/2010). Fur-
ther to this, she represented the LBI-HTA at several meetings on the na-
tional HTA Strategy, the Methodological Handbook for Gesundheit 
Österreich GmbH (GÖG) (16/03/2010, 25/05/2010, 30/11/2010) and at the 
meeting about MEL-development at the Ministry of Health (13/10/2010). On 
18/08/2010, 17/11/2010 and 29/11/2010 she took part at the project meetings 
of the Austrian IFEPH networking project.  
Brigitte Piso is a board member of the Austrian Society for Public Health 
(ÖGPH) and a member of the European Public Health Association 
(EUPHA). Since autumn 2010 she has been a member of the "Prevention" 
working group for the development of a national cancer plan at the Austrian 
Federal Ministry of Health (Meeting on 16/11/2010).  
Further to this, Brigitte Piso carried out the following scientific advisory ac-
tivities in 2010:  
 For the Austrian publication „Early diagnosis of cervical cancer, 
HPV vaccination – Information and Experience - Decision sup-
port“, collaboration with the scientific advisory board, organised by 
the Women’s Health Centre in Graz.  
 
 
individual memberships: 
OSR,  
scientific council of 
bioethics, 
 
scientific advisory 
committee:  
EBM-HVB,  
DAHTA, ZEFQ 
 
advisory board:  
Statistik Austria,  
German Cancer Aid, 
OECD 
Child health dialogue/ 
Ministry of Health 
nat. HTA Strategy/ GO¨G 
MEL/ BMG 
 
IFEDH Project 
O¨GPH 
EUPHA 
WG Prevention – 
national cancer plan/ 
BMG  
Scientific Council  
HPV-vaccine  
decision aid 
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 Invited Expert – Evaluation of the A(H1N1) Influenza Pandemic 
2009/2010 at the „Experience exchange: A(H1N1 influenze pan-
demic in Austria“, at the Gesundheit Österreich GmbH, represent-
ing Claudia Wild, 30/09/2010. 
Marisa Warmuth is a member of the „Child health dialogue: High risk 
pregnancy and birth and their consequences“ working group at the Federal 
Ministry of Health. 
Roman Winkler is a member of the „Child health dialogue: psychosocial 
health“ working group at the Federal Ministry of Health (Meetings on 
08/06/2010; 05/07/2010; 20/09/2010 and 03/11/2010). 
Anna Nachtnebel is a member of the „Epidemiological portrayal, cancer sta-
tistics and documentation“ for the development of an Austrian cancer strat-
egy working group  at the Federal Ministry of Health. Since 2010 she has also 
been a member of the European Horizon Scanning Network „EuroScan“ 
(www. euroscan.org.uk). 
Sabine Geiger-Gritsch is a member of German Society for medical com-
puter science, biometry and epidemiology e.V. (GMDS) and the Interna-
tional Society of Pharmacoeconomics and Outcomes Research (ISPOR). 
Katharina Hintringer is a regular student member of the Senate at the 
UMIT – University for Public Health, Information Systems & Health Tech-
nology Assessment in Hall i.T. 
Philipp Mad is a member of the European Pathway Association  
(www.e-p-a.org).  
Tarquin Mittermayr is a member of the European Association for Health 
Information and Libraries (EAHIL).  
Gerda Hinterreiter is a member of the Austrian Sociaty for Public Health 
(ÖGPH).  
As a member of the Young Gasteiners Network, in 2010 Philipp Radlberger 
was involved in the preparation of conference actitivies, follow-up and on-
site coordination of the European Health Forum, as well as acting as an „as-
sistant rapporteur“ for the EU Commission Forum 3 entitled „EU action and 
local partnerships for health“ and the „Health literacy“ forum. 
Stefan Mathis is member of the Austrian Computer Society and the German 
Network for Health Services Research.  
1.4 Infrastructure 
The office of the LBI-HTA (279 m² in total) consists of seven separate rooms 
and a 70 m² library/seminar room. At the end of 2010, the institute was 
equipped with 16 personal computer workstations. For 2011 no further addi-
tions are planned. 
During the past year the LBI-HTA library has increased its holdings to 735 
monographs. The Institute currently subscribes to eight print periodicals 
and has access to 16 electronic periodicals, as well as the important medical 
and scientific databases Ovid-Medline, Embase, Scopus and UpToDate. 
A(H1N1) expert 
evaluation/ GO¨G 
WG  
Child health dialogue/ 
Ministry of Health 
WG 
 Child health dialogue/ 
Ministry of Health 
WG Epidemiology –
national cancer plan/ 
BMG  
EuroScan 
GMDS & 
ISPOR 
Senate UMIT 
EPA 
EAHIL 
O¨GPH 
Young Gasteiners 
Network 
German Network for 
Health Services 
Research 
office space and 
equipment 
library 
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Because the LBI-HTA intends to enable long-term and free access to its pub-
lications, strong emphasis has been placed on the (further) development of its 
document server (http://eprints.hta.lbg.ac.at) which provides extensive 
search options in English and German. In order to raise awareness of the In-
stitute’s research results internationally, summaries and other relevant in-
formation are regularly sent to the INAHTA office. As a result of this co-
operation, project reports and rapid assessments from the LBI-HTA have 
also been incorporated in the HTA-Database of the Centre for Reviews and 
Dissemination in York, and are accessible via  
http://www.crd.york.ac.uk/crdweb/ 
Tarquin Mittermayr is responsible for the institute's library and provides 
systematic literature searches for the LBI-HTA's scientific staff.  
1.5 Highlights of the Year 
Following the end of the EU „EUnetHTA“ project (2006-2008)“ and the in-
terim project  („EUnetHTA Founding Partner Collaboration 2009“), this co-
operative scheme has now, thanks to long-term funding from the EU coop-
eration network, developed into the „Joint Action 2010-2012“. In this Joint 
Action, the LBI-HTA is leading Work package 7B, with the aim of reducing 
overlaps in EU-wide HTA work. A web-based database of all planned and 
ongoing Assessments (POP database) is to be made available to all 
EUnetHTA partner organisations. To that end, since January 2010 the LBI-
HTA has been collecting all planned and ongoing projects every three 
months. These projects are sorted according to topic and are made available 
to partners. The web-based POP database is currently being developed in co-
operation with the Belgian HTA Institute KCE. It will be completed in June 
2011 and subsequently made available to all contrubting EUnetHTA part-
ners. There has been further cooperation with other EUnetHTA partner or-
ganisations, such as during the LBI-HTA „Horizon Scanning in Oncology“ 
project. Further cooperation, for example in the 2011 MEL assessments, is 
planned.   
Following an initial test of the „Horizon Scanning Systems for Oncology“ 
in 2009, this programme has since been successfully implemented into rou-
tine LBI-HTA practice. 14 Decision Support Documents for Horizon Scan-
ning in Oncology have been published since autumn 2009, including 9 in 
2010. Following regular scanning of (a total of 27) different data sources and 
websites and an initial selection, a group of interdisciplinary experts decide 
for which of these drugs short and concise Assessments should be carried out 
to be passed on to decision makers (pharmaceutical commission). As these 
early assessments are made available around the same time as they are li-
censed by the EMA and are published (only) in English, they have aroused 
significant interest internationally, as well as in Austria. All Horizon Scan-
ning in Oncology Decision Support Documents are available online at 
http://hta.lbg.ac.at/de/content.php?iMenuID=96 
international 
distribution 
international 
cooperation: EUnetHTA 
Joint Action 2010-2012 
LBI-HTA leads WP 7B 
 
reduction of overlaps 
 
 
POP database 
 
further cooperation 
planned 
Horizon Scanning in 
Oncology: 
aroused significant in-
terest 
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Due to apprent EU-wide overlaps, the considerable financial implications 
and the increased demand for the evaluation of oncology drugs, a 2 day 
„Workshop on Onco-drugs“ took place at the LBI-HTA at the end of Sep-
tember/beginning of October. 20 people from 12 European HTA Institutes 
took part, in order to - for the first time - develop options for future coopera-
tion in the rapid evaluation of oncology drugs. This workshop was proposed 
and hosted by the LBI-HTA, as the lead partner of the EUnetHTA Joint Ac-
tion WP 7B. The joint publication of two Horizon Scaning in Oncology As-
sessments with partner institutions (Universitätsklinikum Bremen and the 
Polish institute AHTAPol; early January 2011) is one of the first outcomes 
of this successful get-together. 
The evaluation of individual medical services (MEL) before their inclusion 
in the benefit-catalogue, which was first carried out in 2007/08, is now being 
conducted annually. Completing this task in just a few weeks (mid-January 
to end of March) is not just a methodological challenge, but also as an organ-
isational one; however, with increasing experience it is becoming increas-
ingly routine.  This year, for the second time, the LBI-HTA has cooperated 
with its German counterpart, “NUB/New diagnosis and treatment proce-
dures“, which is often simultaneously faced with similar or identical new 
medical techniques. Again, these assessments have led to a number of scien-
tific publications this year. 
As part of the „EUnetHTA Joint Action 2010-2012“ project (see above), co-
operation with other EUnetHTA partners is planned for the 2011 MEL cy-
cle. As part of this cooperation, joint bilingual (D/E) assessments of „new 
high tech interventions in hospitals“ will be conducted. This project is being 
led by the LBI-HTA within its capacity as co-lead partner of work package 7, 
„New Technologies“. 
11 members of the LBI-HTA team took part in the 11th Annual conference 
of the German Network for Evidence-Based Medicine, “EBM – a gain for 
the Doctor-Patient Relationship?”, which took place in Salzburg on 25th-
27th July.  
On the initiative of the ORAC publishing company, the Institute’s book 
“Zahlenspiele in der Medizin – Eine kritische Analyse” (“Number games 
in medicine – A critical analysis”) was writtenin the second half of 2009. The 
book deals with the often highly suggestiveand therefore potentially mislead-
ing ways in which figures can be presented in the field of medicine. The 16th 
chapter of the book attempts to demonstrate these “number games”, using 
numerous examples which are notable for their impact and/or timeliness. 
The aim of the book is to develop in its readers a certain awareness of these 
figures and statistics, and an understanding of how to interpret them.  
EU-wide cooperation: 
 
 
onco-drugs Workshop 
 
HSS – cooperation with 
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German-Austrian 
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individual medical 
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2011: 
MEL pilot cooperation 
as part of EUnetHTA 
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EBM conference 
Salzburg 
book project „Number 
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The book was compiled by 11 LBI-HTA employees and 3 external experts, 
and edited by Claudia Wild and Brigitte Piso. The book was published by 
ORAC on 08/03/2010. The two editors gave a press conference as part of the 
“Number games in medicine – A critical analysis” book presentation on 
09/03/2010. The press conference was followed by a panel discussion together 
with Martin Sprenger, acting director of the Public Health course at the 
Med. Univ. Graz, Thomas Szekeres, vice-president of the Vienna medical as-
sociation und Wolfgang Wagner, medical and health journalist/APA. The 
dicussion was chaired by Birgit Dalheimer, scientific journalist/Ö1). All LBI-
HTA co-authors attended the book presentation.  
On 07/04/2010 a whole day meeting to develop the research programme for 
the LBI-HTA in 2010/2011 took place at the Berghotel Tulbingerkogel in 
Mauerbach near Vienna. All team members were actively involved in the 
planning and brainstorming for the coming year.  
 
 
 
 
A further highlight of 2010 was the HTAi conference in Dublin (06.-
09/06/2010), which was attended by 13 employees of the LBI-HTA. In addi-
tion to their professional participation, participants used the opportunity for 
international networking.  
 
 
book presentation and 
press conference 
research programme 
planning at the 
Tulbingerkogel 
international 
networking:  
HTAi Conference Dublin 
Annual Report 
2010 
18 LBI-HTA | 2011 
A small delegation of the LBI-HTA team (Smiljana & Darko Blagojevic, Ines 
Schumacher, Gerda Hinterreiter) took part in the 11th Wien Energie Busi-
ness Run on 23/09/2010. At the finish they received their medals proud, 
somewhat relieved and happy.  
 
In order to intensify exchange and cooperation with   
 The Institute for Public Health, Medical Decision Making and 
HTA at the UMIT - The Health and Life Sciences University, 
 The Department for Evidence-based Medicine and Clinical Epide-
miology  at the Danube-University Krems/ DUK, 
 The Federal institute for quality and economy in health care/ BIQG 
and 
 for the first time,  with the EbM Review Center at the MUG/ 
Medical University in Graz , 
a two day networking event, in which 3 LBI-HTA employees took part, took 
place in Melk/Lower Austria the end of September (27.-28/09/2010).  
On 21/10/2010 the Ludwig Boltzmann Society held a large party to celebrate 
the 50th anniversay of the founding of the Society at the Semper Depot 
Wien. The theme of the party was „LBG Meet Science!“. 
At the party, 24 Ludwig Boltzmann Institutes and clusters presented their 
research in short oral presentions. The 400 guests from the Science Commu-
nity were provided with headphones and thus were able to select which of 4 
simultaneous presentations to tune in to. Each presentation was recorded and 
they were later repeated on monitors. Ingrid Zechmeister, the deputy direc-
tor of the LBI-HTA made the LBI-HTA presentation.  
 
Business Run  
national networking 
50 years of the LBG: 
Meet Science! 
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The director of the Institute, Claudia Wild, together with four other LBI di-
rectors, took part in a panel discussion on „Moral courage and research“. In 
her address Beatrix Karl, from the ministry for Science and Research, high-
lighted the great achievements of the LBG as a non-academic research or-
ganisation. Closing remarks were made by Christian Konrad, President of 
the LBG.  
 
The LBI-HTA Christmas party took place on 01/12/2010. It began with a 
tour of the „Over the Roofs of Vienna“ exhibition at the Natural History Mu-
seum, and finished with a cosy meal at the „Roter Elefant“ restaurant.  
 
 
Maria Theresa Square, Vienna, 01/12/2010 
 
 
Naturhistorisches 
Museum &  
„Roter Elefant“ 
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For two HTA employees the private highlight of the year was their respective 
weddings: Ingrid Zechmeister & Christoph (19/06/2010) and Stefan Mathis 
& Susanne (03/07/2010).  
On 14/03/2010 Philipp Mad became a father to little Valentin Eugen Ferdi-
nand. We celebrated these special occasions accordingly.  
1.6 Research Programme 
The work program of the LBI-HTA consists of five programme lines, which 
will be briefly described. All projects will be explained in chapter 2 (re-
search), within the context of the different programme lines. 
Comprehensive assessments of health interventions & evidence-
based health services research 
HTA can now look back on 20 years of methodological developments and in-
ternational harmonisation. „Traditional” assessments answer questions on 
new/innovative or established medical interventions such as  
 Is the intervention effective, does it work? 
 For whom, which subgroup of patients? 
 At what cost? 
 How does the intervention compare with alternatives? 
Unlike traditional HTA, evidence-based health services are still young, but 
are based on the same basic research principles: systematic literature search 
and analysis, transparent presentation of sources, process and results and in-
terdisciplinary perspectives. In contrast to the results from the critical ap-
praisal of medical interventions, the results from health services research are 
deeply anchored in the health systems concerned and cannot be as easily 
transferred into other systems. The research field of evidence-based planning 
follows the approach of distinguishing between demand and need and of 
critically questioning the actual utilisation of health services.  
For that reason, the LBI-HTA, as an HTA institute in a small country, is de-
voted to bringing international HTA into the national context and to further 
developing methods of evidence-based health services research. 
Scientific support of health policy and decision-maker networks 
Policy-relevant decisions are traditionally reached on the basis of a consensus 
of high-ranking experts in boards and committees. This process of exclu-
sively expert-based (so-called eminence-based) decision-making is highly 
prone to bias, conflict of interests and doctrine. It is the aim of evidence-
based support to decision-making to collect and present recent research re-
sults and to provide a more rational and transparent input to the process of 
health policy decision-making, independent of influences from interest 
groups. The aim is to shape the process in the long term by systematically 
questioning marketed information and by asking for sound evidence. 
It is the task of the scientific support of health policy and decision-maker 
networks to react rapidly to demand and to present the evidence to decision-
makers in a transparent and readable format. 
weddings & 
children 
programme line 1 
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Health Technology Assessment in hospitals 
The informal „HTA in hospitals” network consists of a group of about 20 
high-ranking decision-makers (medical directors and quality managers) from 
almost exclusively Austrian hospital cooperation. The network meets twice a 
year (June and October) in order to obtain informative HTA input into 4 key 
topics, to discuss them and to exchange ideas on regulation and reimburse-
ment issues. 
The task of the LBI-HTA is to coordinate the meetings, to request and col-
lect current topics and to prepare the presentations. The format of the meet-
ings is for each topic to be presented from the HTA perspective and by an 
invited clinical expert, which subsequently leads into a structured discussion.  
Scientific decision support of the Health Ministry 
It is the task of the LBI-HTA to provide - on request - scientific support to 
different committees of the Austrian Health Ministry (BMG, 
http://www.bmg.gv.at): 
 to support the Medical Advisory Group in the maintenance of the 
Austrian medical procedure classification (Austrian DRG Cata-
logue) with evidence analysis of new/innovative or established 
medical interventions. 
 to react to information enquiries in the Supreme Health Council 
(advisory committee of the Health Minister). 
Public understanding and research transfer 
Quite often - steered by early media coverage - the demand for 
new/innovative health care interventions emerges, even before market ap-
proval or reimbursement. „Public understanding” is both the transfer of 
knowledge about market forces and about methods for critically questioning 
the evidence presented on effectiveness and cost-effectiveness, appropriate-
ness, and methodological support for the differentiation between new and 
innovative interventions. „Public understanding” is meant to contribute to a 
better understanding of true effectiveness and, at the same time, to a democ-
ratic shaping of benefit packages. 
The intention of „public understanding and research transfer” is to build up 
- through presentations, seminars, monthly newsletter, a user-friendly web-
site and search support - a critical mass of patients, journalists, representa-
tives of the health administration, academia etc. that questions the informa-
tion presented and asks for sound evidence before decision making. 
HTA-implementation: Development and informing on effective policy 
instruments 
Evidence for the effectiveness and cost-effectiveness of numerous technolo-
gies and interventions can often only be presented after market approval and 
several years’ use under real clinical conditions. However, even then, ineffec-
tive technologies are widely spread and applied. Since it is ethically not justi-
fiable to withhold true medical innovations from patients, and because 
pseudo-innovations absorb a lot of resources, taking new technologies under 
„surveillance” or „limited application” at specific medical centres is increas-
ingly frequently considered. Consequently, final decisions on reimbursement 
are made only after patient-relevant outcome data become available. 
programme line 3 
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Methods for limited application and the assessment and appraisal of tech-
nologies and interventions after having obtained patient-relevant outcome 
data are still young. In this programme line, they will be further developed 
and applied. 
International cooperation / HTA Best Practice  
International cooperation and collaboration, particularly within the Euro-
pean Union, is becoming increasingly important in order to avoid redundan-
cies in the assessment of medical technologies prior to reimbursement or in-
clusion in public benefit catalogues. Drugs that have been approved by the 
European regulatory authority EMEA are being launched simultaneously in 
European markets. In addition, medical products and technologies are being 
launched nearly at the same time in European markets.    
The EU-project “EUnetHTA – European Network for Health Technology 
Assessments” is concerned with the development and implementation of 
structures and networks for transnational HTA-cooperation. This project 
was funded by the EU from 2006 to 2008 and was continued without public 
funding throughout 2009. From 2010 until 2012, in the form of a Joint Ac-
tion, it is again be funded by the EU. 
The LBI-HTA was co-initiator and has been a leading partner of EUnetHTA 
for several years. The LBI-HTA manages work package 7 in close coopera-
tion with the French HAS/Haute Authorité de Santé. Work package 7 is con-
cerned with rapid exchange of information on the assessment of new tech-
nologies after their approval but prior to their introduction on the market. 
 
programme line 5 
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2 Research 
2.1 Projects and Scientific Support of Decision-
making 
Classification of severity for neuro- and trauma rehab patients 
Project leader: Brigitte Piso  
Researcher Part 1: Christoph Pammer, Muna Abuzahra  
Researcher Part 2: Muna Abuzahra, Brigitte Piso 
Researcher Part 3: Muna Abuzahra, Brigitte Piso 
Duration: 09/2008 - 05/2010 
Partl 1: Instruments used in classifying stroke and trauma patients  
Part 2: International experiences in applying classification of severity for 
quality-assurance, performance-assessment and reimbursement 
Part 3: Status quo in Austria 
Part 1: 
Background: The evidence that the implementation of quality assurance sys-
tems in neurologic and trauma rehabilitation is able to improve patients´ 
functional health status is low. Indicators for outcome measurement should 
be assessed - not only for quality assurance reasons. Neurologic rehabilitation 
aims to improve the functional health status of patients as well as reintegrat-
ing patients in social participation. Therefore a variety of instruments for as-
sessing functional health outcomes, activity and participation of patients 
have been developed and validated. The comprehensive and multi-
dimensional assessment of patients´ health status is the basis of allocation 
decisions and standardised planning in rehabilitation, as well as coming up 
to the patients´ and the health care providers´ expectations. The selection of 
appropriate measuring instruments makes significant contributions to im-
proved patient care and its treatment outcomes. 
The first part of this project aimed to identify instruments for classifying 
disease severity in patients with neurologic or trauma rehabilitation and as-
sess them according to test quality criteria. As an example, we chose two spe-
cific diagnostic groups (stroke and traumatic brain injury). 
Method: We identified 2527 publications by systematic literature search and 
hand search. 167 full text articles met our inclusion criteria and were in-
cluded in further analyses. 
Results: In stroke patients, specific instruments for classifying the severity of 
the disease show better test quality than generic instruments. Based on test 
quality criteria, we recommend the National Institute of Health Stroke Scale 
(NIHSS), the Beck Depression Inventory (BDI), the Frenchay Activities In-
dex (FAI), the Stroke Impact Scale (SIS) and the Stroke Specific Quality of 
Life Scale (SSQOL). In patients with traumatic brain injury specific instru-
ments do not necessarily perform better than generic instruments. We rec-
ommend the Disability Rating Scale (DRS) and the Community Integration 
Questionnaire (CIQ).  
 
programme line  1 
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Conclusion: Instrument selection is not only dependant on test quality (and 
feasibility and acceptability issues), but also on the purpose the measure-
ments are to serve in the system. Generic instruments can be used across dif-
ferent diseases, while additionally other criteria have to be assessed disease 
specific (modular composition of generic and disease specific instruments). 
In order to choose measurement instruments for neurological and trauma re-
habilitation in Austria, the aims of measurements have to be defined. 
Whether and in which way measurements for quality assurance and outcome 
evaluation will be implemented and whether they will be connected to reim-
bursement needs to be clarified. 
Part 2: 
Background: Neurologic and traumatologic rehabilitation are highly complex. 
The evaluation of quality and performance is important in order to meet the 
requirements of patients, care providers and funders of health care. Increased 
efficiency can be achieved by using outcome-oriented payment models. Dif-
ferentiation by severity of disease using generic (overall diagnosis) assess-
ment instruments could be used in quality measurement and linked to reim-
bursement systems. 
Method: This report considers whether and which generic assessment in-
struments are used in quality and performance measurement, or in determin-
ing levels of reimbursement, in neuro and trauma rehabilitation. In particu-
lar, it explores international experiences with such instruments. A systematic 
literature review and a selective internet search were conducted in order to 
answer these questions. 
Results: In Germany and in Switzerland pilot studies of generic instruments 
for quality and performance measurement are being conducted. In Australia 
the AROC (Australasian Rehabilitation Outcome Centre) carries out quality 
measurement in rehabilitation almost nationwide, and uses the FIM (Func-
tional Independency Measure). The application of generic instruments in 
outcome orientated payment systems has been tested in Germany using the 
FIM and the SINGER (Selbstständigkeitsindex für die neurologische und 
geriatrische Rehabilitation). In Switzerland, the LTR (leistungsorientiertes 
Tarifmodell, performance-oriented tariff model) is currently being tested. In 
Great Britain the RCS (Rehabilitation Complexity Scale), the NPDS (North-
wick Park nursing Dependency Scale), and the NPTDA (Northwick Park 
Therapy Dependency Assessment) have been developed and are currently be-
ing piloted. In Australia the AN-SNAP-Classification (Australian National 
Sub-acute and Non-acute Patient Classification System), in which the differ-
entiation of severity is based on the FIM, has been developed. In the USA the 
FIM has been in use for the differentiation of severity in the PPS (Prospec-
tive Payment System) since 2002. Most of the studies reviewed which discuss 
the use of generic instruments in reimbursement are from the USA. For the 
most part, they evaluate the PPS. The costs of neuro and trauma rehabilita-
tion are higher than the level of reimbursement designated by the PPS. Since 
the implementation of the PPS, the average length of stay has decreased and 
rate of discharges to home has increased. 
Conclusion: Generic Instruments can be used for various purposes. In Austria, 
pilot projects of the use of generic instruments for the measurement of qual-
ity and/or reimbursement, which take into consideration previous interna-
tional experiences and projects, are recommended. 
part 2:  
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Part 3: 
Background: Based on the first parts of the project “classifying disease sever-
ity in patients with neurologic or trauma rehabilitation” (part 1: instruments 
for stroke and traumatic brain injury. HTA-Projektbericht 023a; part 2: In-
ternational experiences with quality / performance assessments and reim-
bursement. HTA-Projektbericht 023b) we aimed to collect status quo data on 
the usage of generic and specific instruments and to identify pilot projects in 
Austrian rehabilitation institutions. Additionally, we wanted to assess opin-
ions about the potential and constraints of generic instruments. 
Methods: For data collection we developed a questionnaire and sent it to 20 
Austrian rehabilitation centers via email (response rate 50%).  
Results: Some instruments (the 10m walk test, the nine-hole-peg-test, the 
Barthel Index/BI, the 2min walk test, the Rankin Scale/RS, the Functional 
Ambulation Categories/FAC, the mini mental state examination/MMSE, the 
expanded disability status scale/EDSS) are being used in almost all of the 
centres, most commonly at admission and/or discharge. Most frequently, 
physicians, nurses, occupational therapists, physiotherapists, speech thera-
pists and (neuro-) psychologists conduct the assessments. Individual goals 
are arranged with patients in all institutions, but goal attainment is evaluated 
in only about fifty percent of the institutions. Key objectives of data collec-
tion are the documentation of the rehabilitation process and documentation 
for internal quality management. Overall seven completed or ongoing pilot 
projects, which test the utilization of measuring instruments or quality as-
surance systems, were identified by the survey. 
Discussion: The results show that recommendations of the ÖGNR lead to a 
homogenisation of the instruments used. However, a standardized guidance 
does not exist and a variety of measurement instruments continues to be 
used. Pilot projects indicate increasing interest in quality management and 
comparison between institutions.  
Publications (Part 1, 2 and 3):  
HTA Project report 23a (Part 1): http://eprints.hta.lbg.ac.at/866/ 
HTA Project report 23b (Part 2): http://eprints.hta.lbg.ac.at/867/ 
HTA Project report 23c (Part 3): http://eprints.hta.lbg.ac.at/879/ 
Haemocomplettan® P and Fibrogammin® P in acquired  
hypofibrinogenemia 
Project leader: Marisa Warmuth 
Duration: 10/2009 – 01/2010 
Background: Haemocomplettan® P and Fibrogammin® P are being increas-
ingly used in the treatment of acquired hypofibrinogenemia to prevent or 
stop particularly perioperative bleeding within Austrian hospitals. Further-
more, decisions regarding the substitution of clotting factor concentrates are 
driven by measuring fibrinogen levels by thrombelastometry (ROTEM®) as 
a point-of-care device.  
Aim and objectives: The aim of this systematic review is to inform decision 
makers about the current evidence regarding the efficacy and safety of fi-
brinogen- and FXIII- substitution with clotting factor concentrates in ac-
quired hypofibrinogenemia. The objectives are firstly, to evaluate whether 
the administration of Haemocomplettan® P and/or Fibrogammin® P is su-
part 3: 
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perior to the substitution of fresh frozen plasma/Octaplas® and/or cryopreci-
pitate in acquired hypofibrinogenemia; secondly, to explore the safety of 
Haemocomplettan® P and Fibrogammin® P; thirdly, to assess whether 
thrombelastometry (ROTEM®) is superior in providing information about 
transfusion requirements compared to standard laboratory hemostasis tests, 
such as the Clauss assay. 
PICO question: Efficacy and safety of Haemocomplettan® P and Fibro-
gammin® P in acquired hypofibrinogenemia in children and adults com-
pared to FFP and Octaplas® with special consideration of ROTEM® point-
of-care testing.  
Method: Systematic Review as outlined in the Internal Manual of the LBI-
HTA. 
Results: The evidence for Hämocomplettan® P is of poor quality. Thresholds 
and dosages for the substitution of fibrinogen concentrate remain unclear. 
Furthermore, the inclusion of heterogeneous, highly selective and critically 
ill patient populations limits the generalisability of results. There is a lack of 
evidence regarding the efficacy and safety of Fibrogammin® P as only one 
study exploring these could be identified. No evidence for the combined use 
of Hämocomplettan® P and Fibrogammin® P could be found.  
Conclusion: In Austria there is an urgent need for national, evidence-based 
transfusion guidelines. Existing guidelines, namely those of the Austrian So-
ciety for Anaesthesiology, Reanimation and Intensive Medicine, as well as 
the internal guidelines of an Austrian University Hosipital are neither evi-
dence-based nor conform with recent guidelines from Canada, the United 
Kingdom or Germany.  
Publication: HTA Project report 39 - http://eprints.hta.lbg.ac.at/870 
Evaluation of diagnostic technologies – Background, challenges, 
methods 
Project leader: Anna Nachtnebel 
Duration: 11/2009 – 08/2010 
Background: Diagnostic technologies are used to confirm or exclude the pres-
ence of disease or to classify disease. Ultimately, test results should influence 
diagnostic or therapeutic decisions, resulting in improved patient-relevant 
outcomes. Because diagnostic tests can also be associated with adverse conse-
quences, and because uncritical use has led to a considerable impact on 
health care expenditure, the identification of efficient and effective technolo-
gies is crucial. In order to ensure a reasonable allocation of resources, evi-
dence-based principles, as for the evaluation of interventions, have to be ap-
plied. In the HTA context, where diagnostics are assessed beyond merely 
their efficacy, taking the most important consequences for patients and for 
health systems into account, unique methodological challenges exist. 
Aims: To give an overview of specific methodological challenges associated 
with the evaluation of diagnostic technologies, and to describe the method-
ologies used by selected institutions for the assessment of diagnostic tech-
nologies. Based on these findings, the aim is to develop a potential method 
for the evaluation of diagnostic technologies relevant to stakeholders. 
Methods:Unsystematic hand-searches (manuals, guidelines, of selected insti-
tutions, Scopus, reference lists of relevant publications) and systematic litera-
programme line  1 
Research 
LBI-HTA | 2011 27 
ture searches of electronic databases (MEDLINE, EMBASE, HTA- database) 
using Boolean operators, MESH terms (e.g. “diagnostics”, “evidence-based 
medicine”) and free text search (e.g. “diagnostic test”, “methodology”, 
“evaluation”) to identify problems and methods used for the evaluation of di-
agnostic technologies. Categorisation of the identified challenges and the de-
scription of relevant methodological approaches of the selected institutions. 
Analysis and synthesis of these approaches to determine a method relevant to 
health systems.  
Results: From the decision-makers‘ perspective, the most important aspect of 
the evaluation of a diagnostic test is the assessment of the patient benefit as-
sociated with it. In order to obtain patient-relevant outcomes, the conse-
quences of the subsequent treatment, as well as the test itself, must be taken 
into account. This may occur directly, in that studies compare the conse-
quences of resulting treatment with those following a comparative test.  Be-
cause these studies are rare, „linked evidence“ provides the possibility to link 
accuracy studies with efficacy studies. However, for „linked evidence“ a 
range of methodological characteristics must be taken into account, and sev-
eral criteria fulfilled. Thus diagnostic accuracy studies may have specific 
methodological problems, such that the evaluation of their quality requires 
specific instruments. Furthermore, the poulation of effeciacy studies and ef-
ficacy studies must be comparable and there must exist a recognised bench-
mark, which these studies can be linked with.  
Conclusions: The institutions included in this study also assess diagnostic 
tests primarily based on their patient benefit and use similar evaluation 
methods. Favoured evaluation methods include systematic reviews; 3 institu-
tions made reference to „linked evidence“. The most frequently mentioned 
instruments for assessing the methodological quality of diagnostic accuracy 
studies are QUADAS, the Cochrane checklist and the STARD Statement; 
the cost-benefit ratio is used by 3 organisations.  
Publication: HTA Projekt report 36 – http://eprints.hta.lbg.ac.at/898 
Radiosurgery: Gamma Knife versus adapted linear accelerator 
Project leader: Stefan Mathis 
Duration: 05/2010 – 09/2010 
Background: In a number of diseases of the brain and associated structures 
the methods of microsurgery are limited. In such situations, radiosurgery is 
an option. Radiosurgery is defined as the biological inactivation or destruc-
tion of intracranial 3D targets by high-precision ionising radiation during a 
single session. Radiosurgery is applicable to patients with primary brain/head 
tumours (menigioma, schwannoma, pituitary adenomas, glioma, melanoma), 
with brain metastases, vascular malformations and a number of functional 
diseases (for instance: trigeminal neuralgia). There are different forms of ra-
diosurgery, including gamma knife, adapted linear accelerators and proton 
beam systems. For this assessment we compared two of these – gamma knife 
and adapted linear accelerator – with a focus on clinical effectiveness and 
cost. The gamma knife is a radiation device that bundles approximately 200 
rays from radioactive sources (cobalt 60) by collimation. The resulting focus 
with a diameter of a few millimetres is called isocenter. A patient is treated 
by positioning his head in such a way, that the isocenter and the patient’s le-
sion overlap. In this position the patient remains fixed (by a stereotactic 
frame), until the therapeutic dose is reached according to the dose distribu-
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tion plan. Because of the high dose gradient (high dose in the centre, low 
doses in the neighbourhood) the surrounding tissue can be protected from 
doses above their radiation tolerance level. The gamma knife is used for pa-
thologies of the head with a diameter of less than 3 centimetres. The com-
parator in this assessment is an adapted linear accelerator (LINAC). LINAC 
is a radiation device which emits X-rays. In contrast to the gamma knife, the 
adapted linear accelerator has only one source of rays. This emitter head 
must therefore be moved around the patient, otherwise (with a single en-
trance point) the tolerance of the tissue in the pathway of the ray would be 
exceeded quickly and, consequently, the therapeutic target dose in the target 
lesion could not be reached. Moving parts (a complex feature of the LINAC 
system) require a vast amount of maintenance and quality control. 
Method: A systematic search in medical databases was performed and com-
pleted using hand searching. The systematic search strategy included all 
studies written in English or German. The population inclusion criteria were 
defined as patients with primary brain tumours, brain metastases, arterio-
venous malformations or trigeminal neuralgia. To be considered for inclu-
sion, studies had to evaluate gamma knife or LINAC based radiosurgery. 
Only studies with a high level of quality in terms of their study design 
(RCTs, prospective cohort studies) were included. For the cost comparison 
the findings from economic literature were analysed and experts interviewed 
about the market situation and the cost components of the radiosurgery pro-
cedure.  
Results: Out of a total of 742 records only few clinical studies made state-
ments about the comparison of both methods. All of them were of low evi-
dence quality (consequently not meeting the inclusion criteria), therefore no 
definite conclusions can be drawn. Three assessments (all from Germany) 
with a similar pool of study questions to this assessment were identified. 
Statements from those studies indicate that gamma knife and adapted LI-
NACs have comparable clinical effects. From studies on the dose distribution 
a slight advantage in precision for gamma knife (especially with very small 
target volumes) and some advantages in homogeneity for the adapted LINAC 
(in bigger target volumes) are reported. The clinical relevance; however, re-
mains unclear in terms of prospective controlled studies. A general lack of 
evidence was observed regarding most of the indications for radiosurgery.  
An annual cost comparison was performed. The higher acquisition costs of 
the gamma knife (~4,000.000 €) are compensated by its longer life span 
(~20). However, gamma sources need to be replaced every 5-7 years, costing 
approximately 700.000 €. An adapted linear accelerator costs ~3,000.000 € 
and has a a life span of ~10 years. Due to the complexity of a LINAC system, 
more maintenance, quality control and therefore personnel resources should 
be expected. On the other hand, a LINAC system can also be used for non-
radiosurgical indications, such as fractionated (more than one session) radia-
tion or extracranial indications. Other cost factors depend on variables that 
are determined by the local context (e.g.: intended indications, case numbers, 
existing equipment and experience). 
Conclusion: There are statements from studies indicating a similar effect of 
both technologies. However, the strength of this evidence is low. If both 
technologies are available, the dose distribution characteristics indicate the 
use of gamma knife for small lesions (better conformity, efficient workflow), 
while the adapted LINAC has advantages with bigger volumes (faster, better 
coverage, homogeneity). Local variables (consented indications, case num-
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bers, existing equipment, experience of personnel) should be carefully evalu-
ated to allow a decision that meets criteria for efficient patient care. From a 
cost perspective, the LINAC system seems to be more versatile in its use and 
therefore recommended, when radiosurgery case numbers are small.  
Publication: HTA Project report 47 - http://eprints.hta.lbg.ac.at/901 
Screening for Colorectal Cancer.  
Part 1: Screening-Tests and Project Design 
Project leader: Claudia Wild 
Project author: Nikolaus Patera 
Duration: 12/2009 – 03/2010, Update December 2010 
Background: Colorectal cancer (CRC) is a malignant tumor arising within the 
walls of the large intestine. Among both men and women CRC was the third 
most common non-skin cancer and also the third-highest cause of cancer 
deaths in the US in 2009. In terms of age-standardized incidence rates, there 
is little difference from one European country to another. CRC has a recog-
nizable, protracted pre-malignant stage that is relatively easy to treat. If the 
disease is detected early, a person’s chances of survival are considerably 
higher than if it is detected at a later stage. That is why various forms of 
screening for CRC have been introduced in a number of countries. 
Aims and research questions: The Swiss cancer league (Krebsliga Schweiz) re-
quested a review of the secondary literature (health technology assessments, 
systematic reviews, meta-analyses) on CRC-screening to inform policy op-
tions in this area in December 2009, and an update in November 2010. 
Research questions: What screening-tests are available for colorectal cancer? 
What are the respective test characteristics and what are the respective tests’ 
wider implications for a colorectal cancer-screening programme? What ques-
tions and central aspects are to be considered in the context of designing an 
organised population-based screening-program for colorectal cancer? 
Methods: A systematic literature search limited to secondary literature (health 
technology assessments, systematic reviews of the literature, meta-analyses) 
published from 1999-2009 was performed in Dec. 2009. This was supple-
mented by a small unsystematic search for literature on recent developments 
in molecular screening-tests. An update search for secondary literature was 
performed in November 2010. 
Results: Colonoscopy is the final common pathway of all screening for colo-
rectal cancer (CRC). For a screening-test in the (healthy) general population, 
colonoscopy is invasive and prone to serious complications. Screening-yield 
and rates of complications are strongly dependent on the individual operator. 
No data is currently available on the impact of CRC-screening on all-cause 
mortality. When considering first-line screening-tests on which to base an 
organized program, the test’s impact on participation is more important than 
its test-sensitivity.  
Conclusion: CT-colonoscopy, capsule endoscopy and new molecular tests are 
not yet viable alternatives for use in population-based mass-screening. 
Publication: HTA Project report 41a - http://eprints.hta.lbg.ac.at/873 
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Screening for Colorectal Cancer. Part 2: Health economic evaluations 
and developments of costs 
Project leader: Ingrid Zechmeister 
Project author: Philipp Radlberger, Ingrid Zechmeister 
Duration: 12/2009 – 03/2010 
Background: During the recent years, several countries have introduced colon 
cancer screening programs. Colon cancer is not only a very common cancer 
in terms of incidence, but several screening technologies exist in addiction to 
colonoscopy, such as the flexible sigmoidoscopy and tests for identification of 
fecal occult blood. 
Aims and research questions: Together with report 41a this study aims to give 
decision support on the question of introduction or/and planning of a colon 
cancer screening program. Therefore it analyses the available evidence on 
cost-effectiveness and cost planning.  
The main research questions are: What health economic evaluations on co-
lon cancer screening programs exist and which screening strategies are more 
cost effective than others/no screening? Which cost factors are most impor-
tant in the planning of colon cancer screening programs? 
Methods: Based on a systematic literature search in databases, the report in-
cludes a systematic review on existing health economic evaluations (system-
atic reviews and single studies). In addition, it answers the question of which 
cost factors are relevant in planning colon screening and to what extent they 
are dependent on each other. 
Results: With costs of about €10.000,- to €20.000,- per life year gained, cost-
effectiveness ratios of the included screening strategies (colonoscopy, flexible 
sigmoidoscopy and fecal occult blood tests) seem to be acceptable compared 
to no screening. However, there are some important limitations in terms of 
unrealistic assumptions about rates of adherence or sensitivity and specific-
ity. The structure of cost plans for colon cancer screening usually include a 
preparatory phase, the actual screening and a period of re-testing and transfer 
into therapy. Depending on the screening method chosen, there are certain 
factors which particularly influence overall costs. They include the manage-
ment of polyps, the need for additional colonoscopies to clarify diagnoses and 
the rate of adherence. 
Conclusion: Based on the evidence available, the implementation of colon 
cancer screening for an average risk population older than 50 years seems jus-
tified in terms of cost-effectiveness, as long as quality assurance is guaran-
teed. 
Publication: HTA Project report 41b - http://eprints.hta.lbg.ac.at/874 
Impact from HTA-research for the Austrian health care system 
Project leader: Ingrid Zechmeister 
Project team: Ines Schumacher, Ingrid Zechmeister  
Durationt: 01/2010 – 12/2010 
Part 1: Methodological overview –update  
Part 2: Results of the empirical survey  
Background: In Austria research in HTA has been conducted since the 1990s. 
Initially, this was lead by the Institute of Technology Assessment at the Aus-
trian Academy of Sciences. Since the Ludwig Boltzmann Institute for HTA 
programme line 1 
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was established in 2006, the importance of HTA research has increased con-
siderably. Research in HTA aims to support an adequate and efficient use of 
health care resources in order to sustain a publicly financed and solitary 
health care system. Research results should provide independent information 
for decision makers. In the long run, HTA should improve the health care 
system (structures, processes, outcomes) and should result in improved popu-
lation health in Austria. In order to legitimise further research resources and 
to prioritise future HTA research and guarantee the value of future research, 
HTA research itself needs to undergo evaluation. 
Aims and research questions: To identify adequate methods for measuring the 
impact of HTA in Austria on the basis of existing literature (part 1)and to 
apply a mix of quantitative and qualitative measures in order to evaluate the 
impact of  HTA in Austria (part 2). 
Methods part 1: Summary of the existing methods for measuring HTA impact 
in terms of definition of HTA impact + indicators and evaluation methods. 
Expert workshop (LBI HTA, UMIT, DIMDI, and University of Bielefeld): 
defining an appropriate evaluation design for an empirical analysis in Aus-
tria. Definition of evaluation tools to be applied in the empirical analysis 
(which followed in part 2). 
Results part 1: A literature review that addresses the methods of measuring 
impact from HTA research has been conducted. The report concludes with a 
framework for measuring the impact of HTA in Austria that is based on pre-
vious work by A. Gerhardus, which was a basis for structuring the empirical 
work as well as an analytical framework for data analysis. Within the frame-
work, impact is classified into 7 categories: awareness, acceptance, policy 
process, policy decision, practice, final outcomes, and enlightenment. Fur-
thermore, different levels of impact (micro, meso, macro) and different target 
groups are addressed. 
Methods part 2: On the basis of the existing framework (part 1), the empirical 
analysis was conducted in part 2 of the project. A mixture of qualitative and 
quantitative research methods was applied to evaluate the impact within tar-
get groups at different levels of the health care system. Impact is evaluated in 
terms of seven categories (mentioned above). The latter means the general in-
troduction of an ‘HTA culture’ in research processes, media reporting and 
decision making. To address these multiple categories we undertook semi-
structured interviews among users, a download analysis, an economic analy-
sis and a print-media analysis and we developed a questionnaire which was 
used among the LBI-HTA staff. 
Results part 2: The impact regarding the categories awareness, acceptance, 
policy process, decision making, practice, final outcomes and "enlighten-
ment" was analyzed using a combination of qualitative and quantitative 
methods. Due to the different methods employed, such as questionnaires, 
discourse analysis, economic analysis, interviews and download analysis, it 
was possible to detect both the impact within the different levels of the 
health system and the various effects arising from HTA research.  
Conclusion: The impact of HTA can be detected in all levels of the health care 
system. Research results are mainly used for decisions at the meso (hospital 
associations) and microlevel (government) of the health care system. A multi-
dimensional impact of HTA within all categories can be confirmed, which is 
still expandable. A lack of impact is strongly linked to external factors (e.g. 
lack of commitment among decision makers, counter-lobbies). Research that 
Annual Report 
2010 
32 LBI-HTA | 2011 
is closely linked to the decision making process in terms of content and time 
frame, standardised inclusion of HTA in decision making processes and re-
source flexibility have been identified as the strongest drivers for future im-
pact. 
Publications: 
Part 1: HTA Project report 37a - http://eprints.hta.lbg.ac.at/877 
Part 2: HTA Project report 37b - http://eprints.hta.lbg.ac.at/907 
Economic aspects of clinically effective and efficient models of 
health services in alcohol addiction treatment 
Project leader: Philipp Radlberger  
Duration: 10/2007 – 04/2010  
Part 1: International models and approaches to outcome measurement (com-
pleted) 
Part 2: Selected models of integrated care and their evaluation (completed) 
Part 3: Comparison of services and costs in practical context: economic 
analysis of therapeutic institutions in Traun and Kalksburg (ongoing) 
Background: Increasingly, psychiatric and socio-medical therapeutic institu-
tions have to deal with the discussion and measurement of their outcomes. 
Given this fact, the project, which is structured in three parts, aims to pro-
duce a synthesis of published knowledge and its analysis in order to gain new 
knowledge for concrete evaluations of therapeutic institutions. Several highly 
heterogeneous approaches exist in the organisation of the services: easily ac-
cessible out-patient therapies, day-care, as well as in-patient services. There is 
relatively little comparative evidence of clinical effectiveness of the different 
approaches, treatment results and costs. 
Aims and research objectives: To give an overview of the different treatment 
models, to analyse some models of integrated care, to reach conclusions about 
the evaluation of cost-effectiveness analysis of in- and out-patient therapies 
for people suffering from alcohol addiction, to transfer the main features of a 
model of integrated care services to the region of Salzburg and to carry out an 
economic evaluation of the existing and a potential integrated care model. 
Methods: 
Part 1: Systematic review, literature- and data analysis; 
Part 2: Additional search of published and grey literature; hand search and 
internet research for chosen models of good practice; direct contact and ex-
pert interviews; systematic organisation analysis of the three examples of in-
tegrated care according to their procedural design, gateway communication 
structures; analysis of grey literature and cost data available; formulation of 
quality indicators which could be benchmarks for other models of integrated 
care in alcohol addiction treatment; 
Part 3: Expert (group-) interviews, clinical and cost data description, cost-
consequence analysis: description of actual structure of financing, definition 
of outcome parameters in clinical records, description of cost data, identifica-
tion of successful treatment in clinical records, cost-consequence analysis. 
Results:  
Part 1: Typologies of diagnosis and treatment planning are internationally 
incoherent. Some systematisations of health services are more advanced than 
others. There is a wide spectrum of alternative treatments including medical 
interventions in short intervention withdrawal, psychotherapies, group-, 
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family- and behavioural therapies as well as relapse prevention measures and 
labour market reintegration facilities. According to the model of service sup-
ply, in-patient, out-patient or day care settings are chosen. Case management 
approaches implying individual carers helping with organising and coordi-
nating flexible treatment structures stand in opposition to treatment strate-
gies where therapy plans are strictly fixed and scheduled immediately after 
diagnosis. In addition to evidence of clinical effectiveness, economic argu-
ments can also influence the structures of health service supply. The fact that 
most countries are initiating screening programs indicates that the economic 
importance of prevention is increasingly recognised. From an organisational 
point of view, general practitioners as gatekeepers can be considered key ac-
tors. 
Part 2: The comparison of three projects on integrated care (combination of 
in- and out-patient treatments) was conducted on three levels: structure, 
processes and results. The “addiction therapy in a linked system/EVS” cen-
tres the gateway management of institutional elements as a key quality indi-
cator for the system by introducing a communication matrix. The evaluation 
of the Jellinek-model uses an adapted quality management tool for enter-
prises. The UKATT, a big RCT with an economic piggyback-design, put the 
focus on clinical outcome parameters. However, all the study authors consid-
ered the retention rate to be highly relevant. 
Discussion: Overall there are many well evaluated single interventions, but 
only very few coordinated models of integrated alcohol therapy. Those that 
do exist are mostly recent, which explains the lack of evidence in the field of 
quality measurement. The analysis of a few regional pilot projects shows the 
high explanatory relevance of gateway management and retention rate for the 
overall quality of a treatment system in alcohol addiction. 
Publication (Part 1 and 2):  
HTA Project report 10 - http://eprints.hta.lbg.ac.at/823/ 
Evaluations of child and adolescent psychiatry 
Project leader: Roman Winkler (overall project, clinical evaluations of project part 1 
and applied evaluation research of project part 2), Philipp Radlberger (economic 
evaluation of project part 1),   
Ingrid Zechmeister (economic evaluation of project part 2) 
Part 1: Clinical and economic evaluations of child and adolescent psychiatry 
(completed). Duration: 10/2008 – 11/2009 
Part 2: Evaluation study at the University Department of Child and Adoles-
cent Psychiatry (Christian-Doppler-Klinik) in Salzburg (ongoing). Duration: 
01/2010 – 12/2011 
Background: The treatment of mentally disordered children and adolescents 
largely uses extensive therapy concepts including medical, psychotherapeutic 
and socio-pedagogical interventions, which are adjusted to patients’ individ-
ual needs. However, in the context of therapeutic evaluations and quality as-
surance, there is a lack of evidence regarding therapeutic outcomes (such as 
clinical improvements, quality of life) and satisfaction rates of patients and 
their relatives concerning therapy care. Additionally, there is a need for long-
term socio-economic outcomes assessing parameters such as school success or 
the working ability of mentally disordered children and adolescents. Re-
search also needs to focus on economic evaluations, which relate therapy out-
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comes to resource management. In Austria, applied evaluation research is 
still in its early stages. Hence, this co-operation shall inter alia contribute to 
improve the Austrian data on quality evaluations. 
Aims and research questions part 1: The first part of the project aimed to pro-
vide a systematic literature review regarding evaluation methods, to identify 
applied evaluation instruments and to analyse systematically therapy out-
comes such as clinical symtomatology, health-related life quality, patients’ 
satisfaction rates, long-term socio-economic outcomes and the cost effective-
ness of treatments. The overall aim was to identify adequate benchmarks for 
the Austrian context. 
Hence, project part 1 was based on the following research questions: 
 Which evaluation indicators and which methods and instruments 
have been used to evaluate treatment programmes for mentally dis-
ordered children and adolescents within the international context? 
(HTA project report number 27). 
 Which therapy outcomes have been identified so far and which ones 
can be identified as benchmarks for the Austrian context? Which 
long-term socio-economic outcomes have been empirically ana-
lysed? (HTA project report number 27). 
 Which costs, cost-effectiveness ratios and cost-benefit analyses have 
been documented in economic evaluations? (HTA project report 
number 28). 
Methods part 1: Systematic literature search of studies/reports in medical por-
tals (Ovid Medline, Embase, CRD databases, PsycINFO, EconLit, ISI Web 
of Science), period 1985-2009; hand search; analysis; systematic literature re-
view. 
Results part 1:  
Clinical findings: The systematic review showed the therapeutic outcome, 
treatment satisfaction and the health-related quality of life of the patients 
turned out to be the primary evaluation dimensions. Evaluation indicators 
have been developed for the purpose of defining these dimensions. In this 
context, the clinical symptomatology was identified as a core indicator for 
medical, psychotherapeutic and psycho-social treatment programmes. The 
quality of the treatment process as well as the “communication culture” 
among the involved actors, were proposed as adequate evaluation aspects. 
This also linked to health-related quality of life issues focusing even more 
strongly on the assessement of the patient’s own human resources. In most 
cases, standardised empirical instruments were used to measure the evalua-
tion indicators. The “MARSYS” system was of particular interest because of 
its comprehensive view of aspects relevant to treating mentally disordered 
children and adolescents. Regarding the study results, study authors of the 
selected publications widely report significant improvements in terms of the 
clinical symptoms. Regarding the “success factors” related to improved clini-
cal outcomes, the building of “sustainable relationships” during the course of 
treatment appears to be core for the initiation of “successful” treatments.  
Economic findings: Over a period of 25 years, one systematic review and 25 
single evaluations could be identified. Some indications, e.g. ADHD, have 
been more frequently studied than others. Regarding different interventions, 
there is disequilibrium in favour of family therapy interventions. Most of the 
evaluations are cost-effectiveness studies. Results suggest that the cost-
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effectiveness of the interventions assessed is low, compared to interventions 
evaluated in somatic medicine. Most of the studies identified are inade-
quately transparent, especially with regard to information on cost data collec-
tion and modelling. The transferability of the evidence is limited because 
studies looked at context specific interventions. As for the collection of cost 
data, most studies take a public payers’ or insurance company perspective. 
Further to this, there are instruments, such as the ‘Client Service Receipt In-
ventory’, which do not only cover expenses incurred within the public health 
system, but also other public or private costs. 
Aims and research questions part 2: On the basis of these “theoretical reflec-
tions” on clinical and economic evaluation studies, further research activities 
will take place in co-operation with the University Department of Child and 
Adolescent Psychiatry at the Christian-Doppler-Clinic (Salzburg) from 
March 2010 onwards. This forthcoming project part 2 pursues the aim to 
make use of those therapy outcomes that turned out to be adequate and use-
ful (according to the systematic reviews) in order to evaluate treatment pro-
grammes in Salzburg.  
The following research questions will guide the research in project part 2: 
 Which clinically relevant changes and developments show children 
and adolescents who make use of the treatment programmes offered 
by the University Department of Child and Adolescent Psychiatry 
at the Christian-Doppler-Clinic (Salzburg)? 
 Which resources have been used before and during the hospital 
stay? How can we understand the relation between treatment needs, 
costs and therapy outcomes?  
Methods part 2: Primary data surveys at the University Department of Child 
and Adolescent Psychiatry at the Christian-Doppler-Clinic (Salz-burg); 
Quantitative (e.g. “MARSYS” questionnaires) and qualitative (inter-views 
with patients, parents) instruments of Social Sciences Research.  
Publications:  
HTA Project report 27: Evaluations of child and adolescent psychiatry. The-
ory and practice about measurement dimensions, indicators and instruments 
(Roman Winkler)-  http://eprints.hta.lbg.ac.at/846 
HTA Project report 28: Child and adolescent psychiatry part 2: A systematic 
review of health economic evaluations (Philipp Radlberger, Ingrid Zechmeis-
ter) - http://eprints.hta.lbg.ac.at/862  
Reshaping maternity and child care prevention programmes in Aus-
tria 
Project leadere: Brigitte Piso  
Project team: Marisa Warmuth, Roman Winkler, Ingrid Zechmeister, Philipp 
Mad, Ines Schumacher 
Additional project conttribution: Claudia Wild, Stefan Mathis, Tarquin Mitter-
mayr, Imke Schall, Tina Loibl 
Duration: 04/2010 – 03/2011 
Part 1: Epidemiology and assessment of risk-factors as well as diseases 
Part 2: International instruments and “models of good practice” of mother-
child health care services 
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Part 3: Economic analysis 
Part 4: Synthesis of parts 1-3, recommendations for actions  
Background: The mother-child-pass examination programme was launched in 
Austria in 1974. Since then, the spectrum of examinations has been steadily 
extended and the number of examinations has continuously increased. How-
ever, to date, neither the programme itself nor recently emerging needs have 
been systematically evaluated. An evaluation of the Austrian mother-child-
pass examination programme primarily aims to analyse the specific needs of 
the target population in terms of the breadth and depth of both existing ser-
vices and new/ different services required, as well as challenging the evidence 
base of existing examinations. 
The mother-child-pass examination programme is a classical (epidemiologi-
cal) screening programme among healthy individuals. However, WHO crite-
ria for screening should be applied. Currently, the mother-child-pass exami-
nation programme comprises of examinations of both the pregnant mother, 
from the point of detection of pregnancy until delivery, and the child, from 
birth up to the 62nd month of life. The current mother-child-pass is pre-
dominantly “medicine-focussed” and more or less excludes diagnostic proce-
dures/ care provided by health professionals other than doctors, such as 
midwives, nurses, physiotherapists, psychologists, social workers, besides 
others. However, this contrasts with more recent regional / national and in-
ternational screening models targeting primarily at-risk populations (e.g. so-
cially deprived women and children, women and children with a migration 
background etc.) that have special needs related to mother-child health care 
services.  
Program services have mainly been publicly financed by several public pay-
ers. Additionally, different incentive systems have been introduced to in-
crease uptake of services. In order to establish a system of care that meets 
current needs, adequate financing structures, among other things, are re-
quired. 
Aim of the overall project: The aim is the development of a decision support 
document for the re-orientation of the mother-child prevention programme 
in Austria. It aims to ease the re-organisation process for stakeholders in or-
der to adjust the prevention programme to the actual needs of the relevant 
target population. 
Objectives: 
 Part 1: A synthesis and analysis of epidemiological data concerning 
existing risk factors and diseases in defined target-groups aims to 
highlight the spectrum of risk factors and diseases, including their 
frequency. It should provide the basis for the assessment of services 
required.  
 Part 2: The second part will cover a comparative analysis focussing 
on similar screening-instruments in the international context – on 
the one hand, this shall involve experiences relating to particular 
services provided for risk populations, as well as, on the other hand, 
other innovative services aspects for mother-child health.  
 Part 3: Part three will describe the financing structures (payers, 
monetary flows, transfer of services), the inherent incentives as well 
as costs and expenditure of current services (mother-child-pass ex-
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aminations and other preventive measures for pregnant women, 
newborns and children). 
 Part 4: Based on the results of parts 1-3 we aim to assess the actual 
needs in terms of services required. 
Methods:  
 Part 1: Systematic literature search in the following databases: 
CRD-INAHTA, Embase, Ovid Medline, PsycINFO, PSYNDEX, 
The Cochrane Library, Web of Science und MedPilot; Hand search 
in databases, selected medical journals, committees of professional 
societies, HTA-institutions; Synthesis of statistical data from Aus-
tria (Statistik Austria, birth registry, health reports) concerning dis-
eases/ risk-factors/ risky behaviour; Comparison of assessed statisti-
cal data with the current mother-child-pass examination programme 
concerning examinations/ missing examinations/ lacking data; 
Workshop with national experts 
 Part 2: Internet search on public sector information; Systematic lit-
erature search and hand search in databases; Questionnaire; Com-
parative analysis of international screening-instruments and ser-
vices; Workshop with national experts 
 Part 3: Evaluation of public documents on financing structures and 
legal frameworks; Interviews with payer representatives to gain ad-
ditional information; Analysis of costs and expenditure based on 
administrative data (e.g. from social security funds and hospitals, 
ministry) and on secondary literature 
 Part 4: Synthesis of results of parts 1-3; Comparison of contents/ fi-
nancial structure of the current maternity and child care programme 
with identified risks and international approaches 
Strengthening the knowledge base for a better health system in Austria: 
Inspirations from abroad for capacity building in health services and pub-
lic health research 
Project leader: Claudia Wild 
Project team: Nikolaus Patera 
Duration: 06/2010 – 01/2011 
Background: Important sectors of society require specific knowledge for goal 
oriented organisational activity. This is particularly relevant for the complex 
field of public health and health care. Health Services and Public Health re-
search can develop such knowledge and offer it to policymakers and practice. 
Aims and research objectives: This project strives to enable learning from good-
practice examples of capacity building in the areas of health services and 
public health research. Specific organisations abroad which work in this field 
(e.g. Institutes of Public Health, Institutes for Health Services Research, Sci-
entific Advisory Councils, Research-commissioning Institutions) and their 
interactions with policy makers and practice are to inspire the Austrian 
situation. The following research questions should be answered: 
 Theoretical questions: What sort of knowledge base is necessary for 
developing health systems? What does the interaction between re-
search and policy look like? What kind of institutions, which corre-
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sponding organisational culture, which work processes, what sort of 
networks and which financial investments into additional resources 
can help facilitate this research – policy interaction? 
 International good practice: How do selected countries with potential 
role model characteristics for Austria structure their relevant insti-
tutions? 
 Recommendations for Austria: Taking clues from the literature on 
knowledge generation and transfer and integrating aspects of good 
practice institutions abroad, what profile results for an Austrian 
“Institute of Health Services and Public Health Research”? What 
should its organisational culture look like? According to which 
processes should it work? What resources are necessary? What can 
Austria do to aid capacity building in health services and public 
health research? Which processes for commissioning research, for 
inter-institutional networking and exchange in the debate over pol-
icy relevant research issues, which mechanisms for research evalua-
tion and which steps towards bridging the research – policy divide 
are desirable? 
Methods: Non-systematic hand search for literature on the relevant knowl-
edge base for health care systems, on capacity building in health services and 
public health research and on the research – policy interaction; Internet 
search on homepages of institutions potentially representing good-practice 
(organizational structure, resources, work processes, research output); Semi 
structured expert interviews with institutions and stakeholders from the 
relevant organizational environment in selected countries via telephone. 
Measuring disease – Patient-relevant outcomes versus surrogate out-
comes 
Project leader: Anna Nachtnebel 
Duration: 09/2010 – 04/2011 (Part 1); 05/2011 – NN (Part 2) 
Background: Health technologies should eventually lead to improvements in 
patient-relevant outcomes, defined as “a measure of how a patient feels, func-
tions or survives”. Nevertheless, because surrogate outcomes are more readily 
available and often easier to measure they are increasingly used as substitutes 
for clinically relevant endpoints. Consensus exists that only validated surro-
gates should serve as substitutes for patient relevant outcomes, but despite 
this claim, the literature is somehow patchy regarding which surrogates are 
commonly accepted and valid endpoints and therefore constitute outcome 
measures eligible for licensing or reimbursement decisions. Accordingly, 
HTA agencies often face the problem, especially with regards to new tech-
nologies, that only sparse data on patient-relevant outcomes are available. 
This might result in either the incorporation of endpoints with unknown 
relevance to the technology’s actual benefits and risks into assessments, or in 
the exclusion of studies without patient-relevant outcomes, which might bear 
the risk of loosing a great deal of information. This poses the question 
whether a catalogue of widely accepted and validated surrogate parameters 
can be formulated to facilitate incorporation of surrogate outcomes in HTA 
reports.    
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Aims part 1: 
 To elicit methodological considerations and requirements necessary 
for the validation of surrogate outcomes.  
 To clarify if the composition of a catalogue (preferably arranged ac-
cording to groups of diseases) with validated surrogate parameters is 
possible and feasible.  
Research questions part 1: Which instruments are available to measure disease 
(patient reported vs observer rated outcomes, generic vs disease specific in-
struments)? What are the definitions for patient-relevant outcomes and sur-
rogate outcomes? Which criteria have a parameter to fulfil in order to serve 
as a valid surrogate? Which methods can be used to establish validity of sur-
rogates? What do the methodological guidelines of HTA/licensing institu-
tions (FDA, EMA) state on using surrogates to assess clinical benefit? What 
are the context specific circumstances which justify use of surrogates as pri-
mary outcomes in clinical trials? Can these circumstances be used to derive 
more general recommendations on when surrogates might be justified? Is the 
validation of surrogates disease-specific (including dependency on line of 
therapy as in cancer drugs), technology specific or can commonly accepted 
surrogates be established which are valid for broader groups of indications?  
Methods part 1: Systematic literature search; Unsystematic search (Home-
pages of licensing (FDA, EMA) and HTA institutions, reference lists of rele-
vant articles, gray literature) 
Aims part 2 (dependent on findings of part 1): 
 To compile a catalogue of valid surrogates for indications most rele-
vant to the LBI-HTA; 
 In-depth discussion of underlying methodology/problems associated 
with measuring disease for these indications,, e.g. patient-reported 
outcomes versus observer reported, generic measures vs disease spe-
cific measures; 
Preliminary research questions part 2: Which groups of diseases are most often 
subject to assessments conducted by the LBI-HTA? What are the methodo-
logical difficulties associated with measuring either surrogates or clinically 
relevant outcomes for these diseases? Which surrogates are commonly used 
as outcome measures for these diseases? Is there evidence available or can 
evidence be generated that these surrogates are valid?  
Preliminary methods part 2: Analysis of LBI-HTA assessments according to 
disease group, indication, technology assessed, outcome parameters consid-
ered; Discussion of outcome parameters for interventions/diseases by indi-
vidual researchers of the LBI-HTA, including consideration of patient-
relevant outcomes versus surrogates, patient-reported versus observer rated 
outcomes, available instruments (generic vs disease specific instruments). 
Topics might include: (paediatric and juvenile) psychiatry interventions, re-
habilitation programmes, back pain, cancer therapies and cardiovascular dis-
ease; Un-/systematic literature search (this might comprise systematic review 
on specific parameters and/or diseases/indications, unsystematic search in 
HTA databases). 
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Hyperthermia  
Project leader: Stefan Mathis 
Duration: 12/2009 – 07/2010 
Background: Hyperthermia is an intervention that uses microwaves to heat 
target tissue up to 41-45° Celsius. In clinical studies hyperthermia is evalu-
ated as supplementary tumour therapy in combination with radiation ther-
apy or chemotherapy is certain tumour stadiums. A comprehensive German 
assessment from 2005 (commissioned by the Federal Joint Committee of the 
German Health Care System – GB-A) concluded from their summary of the 
evidence, that hyperthermia is not recommended for routine use. The cur-
rent assessment summarises the evidence after the 2005 German review for 
11 (promising) tumour indications and evaluates whether the status of evi-
dence has changed since then.  
Method: Medical databases and Health Technology Assessment databases 
were systematically searched for studies that evaluate hyperthermia. The se-
lection process was based on predefined inclusion criteria and is documented 
using a PRISMA Flowchart. For all studies the quality of evidence was as-
sessed. Finally the evidence from the studies was summarised based on par-
ticular outcomes (using the GRADE method). This was the basis for a rec-
ommendation for current use.  
Results: 6 RCTs and a long-term follow up of an RCT were included. No 
other prospective controlled studies could be identified. The studies report 
the application of hyperthermia within the following indications: rectal car-
cinoma (1 study and 1 long term outcome), breast cancer (1 study), cervical 
carcinoma (1 study), melanoma/superficial (2 studies) tumours and anal tu-
mours (1 study). The quality of the collective evidence is moderate to low, 
because there was predominantly only one study per indication and the ma-
jority of the studies had limitations. The majority of the studies do not show 
a benefit for the endpoints survival or quality of life. A few studies show an 
advantage in the endpoint local control, but this term was defined inconsis-
tently and some criticisms exist as to whether the measurement of local con-
trol is convincing. Other studies show a clear negative effect of additional 
hyperthermia. The majority of studies report a high rate of acute toxicity.  
Discussion: The results of studies assessing survival and quality of life do not 
show a benefit of hyperthermia. The result from local control based outcomes 
show a heterogeneous picture and there relevance for patients is partially un-
clear. Acute side effects are reported frequently where hyperthermia is ap-
plied. The collective evidence is too limited to conclude a beneficial effect for 
patients. Results of new Phase III studies are that may strengthen the evi-
dence for hyperthermia are expected shortly. 
Conclusion: The use of hyperthermia can not be generally recommended, be-
cause the strength of the evidence (on time of this assessment) is too weak to 
conclude a net benefit. Hyperthermia should therefore only be applied 
within clinical studies.  
Publication: Decision Support Document 36 - http://eprints.hta.lbg.ac.at/883 
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policy advice/ Decision 
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Research 
LBI-HTA | 2011 41 
Evaluation of individual medical services (MELs) 
Project leader: Claudia Wild, Philipp Mad 
Duration: 01/2010 – 04/2010 
Background: Each year, the Austrian Ministry of Health receives suggestions 
for numerous new medical interventions to be reimbursed. The aim of this 
project is to evaluate the efficacy and safety of interventions suggested for in-
clusion in the MEL (German for: individual medical services) catalogue. 
Themes (interventions) are prioritized by the Ministry of Health and con-
tracted out to the LBI-HTA.  
The assessments are based on systematic reviews for each intervention and a 
summary of the scientific evidence according to the GRADE scheme. Since 
2009 the LBI-HTA has cooperated with its German counterparts,„NUB/ 
Neue Untersuchungs- und Behandlungsmethoden“ , which also appraises, 
relevant new medical interventions, using the same method.. 
For the first time, international cooperation with other EUnetHTA partners 
is planned in the context of the EU project „EUnetHTA Joint Action 2010-
2012“ (see Chapter 1.5) for the 2011 MEL cycle. Within this framework, bi-
lingual (D/E) MEL Assessments will be jointly carried out.   
Results: In 2010 a total of 5 Decision Support Documents as well as 5 Updates 
were written:  
 Laser angioplasty of coronary arteries 
 DSD 39: http://eprints.hta.lbg.ac.at/885 
 Mitral valve repair using a mitral clip (in cooperation with MDS/ 
DE) 
 DSD 41: http://eprints.hta.lbg.ac.at/888 
 High intensity focused ultrasound (HIFU) for the treatment of 
prostate cancer 
 DSD 37: http://eprints.hta.lbg.ac.at/887 
 Artificial disc replacement 
 DSD 38: http://eprints.hta.lbg.ac.at/886 
 Radionuclide therapy - 90Yttrium and 177Lutetium somatostatin 
analogues for the treatment of inoperable neuroendocrine tumors 
 DSD 40: http://eprints.hta.lbg.ac.at/889 
5 MEL- interventions updates 2010: 
 Kyphoplasty and vertebroplasty for osteoporotic vertebral com-
pression fractures 
 DSD 08/ Update 2010: http://eprints.hta.lbg.ac.at/890 
 Stent-grafting of the ascending aorta 
 DSD 14/ Addendum 2010: http://eprints.hta.lbg.ac.at/892 
 Cardiac contractility modulation for heart failure 
 DSD 15/ Update 2010: http://eprints.hta.lbg.ac.at/893 
 Percutaneous aortic valve replacement 
DSD 18/ Update 2010: http://eprints.hta.lbg.ac.at/894 
 Endobronchial valve implantation for emphysema 
DSD 20/ Update 2010: http://eprints.hta.lbg.ac.at/891 
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Methods: The assessments are based on systematic reviews, which are con-
ducted for each intervention, and summaries of the evidence based on the 
GRADE framework.  
Publications (all): http://hta.lbg.ac.at/de/content.php?iMenuID=101 
HTA in Hospitals: Organisation and coordination of a decision-
makers network  
Programm leader: Claudia Wild 
The informal „HTA in hospitals” network consists of a group of about 20 
high-ranking decision-makers (medical directors and quality managers) from 
almost exclusively Austrian hospital cooperation. The network meets twice a 
year (June and October) in order to obtain informative HTA input into 4 key 
topics, to discuss them and to exchange ideas on regulation and reimburse-
ment issues. 
The task of the LBI-HTA is to coordinate the meetings, to request and col-
lect current topics and to prepare the presentations. The format of the meet-
ings is for each topic to be presented from the HTA perspective and by an 
invited clinical expert, which subsequently leads into a structured discussion.  
HTA in hospitals, 23/03/2010: 
Topics and presentations: 
 Haemocomplettan® P and Fibrogammin® P in acquired hypofi-
brinogenemia (Marisa Warmuth, LBI-HTA)  
 Head-to-Head Studies: Avastin  vs. Lucentis (Susanne Binder, 
KAV-Vienna) 
 Evidence-based planning of PET (Markus Narath, KAGes-Stmk)  
 Horizon Scanning: New Onkology drugs (Anna Nachtnebel, LBI-
HTA)  
4 short presentations on 2010 MELs:  
 Mitral valve repair using a mitral clip (Philipp Mad, LBI-HTA) 
 HIFU - High intensity focused ultrasound for the treatment of pros-
tate cancer (Marisa Warmuth, LBI-HTA) 
 Artificial disc replacement (Ingrid Zechmeister, LBI-HTA) 
 Radionuclide therapy - 90Yttrium and 177Lutetium  somatostatin 
analogues for the treatment of inoperable neuroendocrine tumors 
(Christopher Adlbrecht, MUW/ LBI-HTA) 
4 short presentations on „old MELs“: 
 Hyperthermia as an adjuvant in the therapy of designated tumor 
diseases (Stefan Mathis, LBI-HTA) 
 ACI/ Autologous Chondrocyte Implantation (Claudia Wild, LBI-
HTA) 
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5 short presentations on MEL-Updates 2010: 
 PAK - Percutaneous aortic valve replacement (Claudia Wild, LBI-
HTA) 
 CCM - Cardiac contractility modulation for heart failure (Philipp 
Radlberger, LBI-HTA) 
 Endobronchial valve implantation for emphysema (Anna Nachtne-
bel, LBI-HTA) 
 Stent-grafting of the ascending aorta (Brigitte Piso, LBI-HTA) 
 Kyphoplasty and vertebroplasty for osteoporotic vertebral compres-
sion fractures (Brigitte Piso, LBI-HTA) 
HTA in hospitals, 12/10/2010: 
Topics and presentations: 
 Evaluation of diagnostic technologies – background, challenges, 
methods (Anna Nachtnebel, LBI-HTA) 
 Diagnostic pathways with quality and economic impact (Dir. Dr. 
Franz Harnoncourt, KH der Elisabethinen Linz) 
 PROP/ Preoperative appraisal (Dr. Gerhard Fritsch, SALK) 
 PROP/ Preoperative appraisal (Dr. Vinzenz Huber, BVA) 
 Approaches to the reduction of diagnostics (Dr. Tilman Königswie-
ser, GESPAG) 
 Diagnostic (and therapeutical) pathways in heart attacks in Carin-
thia (Prim. Univ.-Prof. DDr. Georg Grimm, KABEG) 
 Approaches to the reduction of diagnostic costs (Dir. Mag. Gebhard 
Falzberger, KAGES, LKH-Univ. Klinikum Graz) 
Methods: Presentations, Discussions 
The intention of programme line 3 „Public Understanding and Research 
Transfer“ is to build up - through presentations, seminars, trainings, a 
monthly newsletter, a user-friendly webpage and search support - a critical 
mass of patients, journalists, representatives of the health administration, 
academia etc. that questions the information presented and asks for sound 
evidence before decision making. 
Project leader: Claudia Wild, Gerda Hinterreiter 
The seminar series "decision-support in health care" addresses the health 
administration, journalists, academia in health care and the interested gen-
eral public. Two to six presentations are offered per year, with free admis-
sion. Duration: about two hours including scientific discussions. In 2010 
three seminars were organized and attended by 15 to 25 persons. 
Expensive 'innovations'- rational and safe use of new agents in oncology" 
25/01/2010 | 15:30-17:30 | Gesellschaft der Ärzte, Vienna 
Lecturer: Univ.Prof. Dr. Wolf-Dieter Ludwig 
Chair of the pharmacy commission of the German medical fraternity and chief physi-
cian at the Clinic for Haematology, Oncology and tTumour Immunology at the He-
lios Clinic Berlin 
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Number games in reproductive medicine: The calculation of success  
15/12/2010| 16:00-17:00 | LBI-HTA 
Lecturer: Univ.-Doz. DDr. Barbara Maier  
Director of the clinic for gynaecological endocrinology and assisted reproduction at 
the University Clinic for Gynaecology and Obstetrics, Salzburg  
IVF, premature birth and neonatology - Resource utilisation  
15/12/2010| 17:00-18:00 | LBI-HTA 
Lecturer: Univ.-Prof. Dr. Angelika Berger  
Interim director of the department for neonatology, paediatric intensive care and neu-
ropaediatrics at the University Clinic for Paediatrics, Vienna 
For the employees of the LBI-HTA, methodological training sessions are 
given by experts two to three times a year. External colleagues can also be in-
vited to attend.  
Performance-oriented hospital financing, documentation  
and accounting  
04/05/2010| 15:00-17:00 | LBI-HTA 
Lecturer: Dr. Christian Rous (KAGes) 
Health care data/ Data sources: Health care planning in Austria 
02/06/2010| 15:00-17:00 | LBI-HTA 
Lecturer: Dr. Gerhard Fülöp (ÖBIG) 
IVF – Successes, failures 
01/09/2010| 16:00-17:30 | LBI-HTA 
Lecturer: Univ.-Doz. DDr. Barbara Maier (SALK) 
The aim of the HTA Newsletter, which is regularly published online, is to 
summarise international HTA results in the form of short, easy to read arti-
cles. For each Newsletter, four articles about relevant technolo-
gies/interventions are selected. Often, but not always, topics which at least 
two different HTA institutions have worked on and published independently 
are chosen. An editiorial, often penned by an invited expert, deals with inter-
disciplinary topics: methodological issues, health policy issues etc. The 
HTA-Newsletter (which was published by the Austrian Academy of Sciences 
between 2001 and 2006 and has since been published by the LBI-HTA) is 
published 10 times per year; November 2010 saw the publication of its 92nd 
edition.  
The HTA Newsletter, which is sent to approximately 900 people in Austria 
and Germany via the HTA mail distributor, has continued to receive positive 
feedback.  
The HTA-Newsletter download page of the LBI-HTA 
(http://hta.lbg.ac.at/de/newsletter.php?iMenuID=63) received between 641 
(July) und 1.533 (November) hits per month in 2010, with a total number of 
13.937 hits.  
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Figure 2.1-1: Download HTA-Newsletter 2008, 2009 & 2010 
Project leader: Claudia Wild, Gerda Hinterreiter  
Duration: 10 x p. a. 
The work of the LBI-HTA or its employees featured in 42 articles, press re-
leases, radio and TV interviews in 2010. These were: 
Die Umstrukturierung, die niemand mitbekommen hat 
Date: 22/12/2010 
Medium: Wiener Zeitung 
Article 
 
Zahlenspiele in der Medizin 
Date: 16/12/2010 
Medium: ZEFQ - 104 (2010) S. 743 
Book review 
 
Junge Hausärzte sind Mangelware 
Date: 02/12/2010 
Medium: Die Furche 
Article 
 
Die Gesundheitsversorgung in Österreich ist teuer und extrem ungerecht 
Date: 27/11/2010 
Medium: Profil (print & online) 
Article 
 
Im Zentrum: Krankes System - Wird Gesundheit unbezahlbar? 
Date: 21/11/2010 
Medium: Im Zentrum (ORF 2) 
Live TV discussion  
 
 
 
 
press review 2010:  
42 articles/ 
contributions  
Download HTA-Newsletter 2008, 2009, 2010
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Die Medien sind ja nur Instrumente 
Date: 04/11/2010 
Medium: Netdoktor.at (Sprechstunde) 
Interview 
 
Das LBI-HTA kurz vorgestellt von Dr. Ingrid Zechmeister, MA 
Date: 21/10/2010 
Medium: LBG Meet Science! (50 Jahre LBG, Seper Depot Wien) 
Short presentation (Video online) 
 
Claudia Wild direkt gefragt: Unfallopfer in die Gremien berufen 
Date: 09/2010 
Medium: VCÖ-Magazin 04/2010 (print + online) 
Article 
 
ein'gSCHENKt mit Claudia Wild, Direktorin des Ludwig Boltzmann In-
stituts für Health Technology Assessment - Zahlenspiele in der Medizin 
Date: 19/08/2010 
Medium: Okto 
TV review + Webtext  
 
Geht's uns zu gut?  
Date: 06/08/2010 
Medium: Die Presse (print & online) 
Article 
 
Auf dem Holzweg in die Sackgasse 
Date: 06/2010 
Medium: Hausarzt, 6/10, S. 36 
Article 
 
Die Medikamente sind viel zu teuer 
Datum: 30.05.2010 
Medium: Blick.ch (online) + Sonntagsblick (print) 
Textsorte: Artikel 
 
Hausärzte sollen kritischer sein 
Date: 26/05/2010 
Medium: Medical Tribune , 42. Jg. Nr. 21 
Article 
 
Erschütternde Medizinstudie enthüllt: Tausende Patienten könnten noch 
leben 
Date: 23/05/2010 
Medium: Kronzen Zeitung 
Article 
 
Hausärzte-Diskussion 
Date: 21/05/2010 
Medium: Format 
Follow-up report 
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Erforscht oder erkauft? 
Date: 20/05/2010 
Medium: Ärztemagazin 20/2010, S. 6 
Article 
 
Medizin hält Studien zurück 
Date: 19/05/2010 
Medium: Wiener Zeitung (print & online) 
Article 
 
Schlicht obszön 
Date: 17/05/2010 
Medium: Der Spiegel 20/2010, S. 166 
Article 
 
Wie Pharmafirmen Stimmung machen 
Date: 14/05/2010 
Medium: Wiener Zeitung (print & online) 
Article 
 
Auf dem Holzweg in die Sackgasse: Medizinische Erkenntnisse - er-
forscht oder erkauft? 
Date: 11/05/2010 
Medium: Radiokulturhaus, ORF Kulturcafé - Ö1 
Radio review & announcement text 
 
Störfaktor Patient 
Date: 04/2010 
Medium: CliniCum 04/2010, S. 6 
Article 
 
Zahlenspiele in der Medizin 
Date: 30/04/2010 
Medium: Hausarzt 04/2010, S. 37 
Review 
 
EBM in Salzburg: Machen wir's doch in Salzburg! 
Date: 21/04/2010 
Medium: Qualitas 01/2010 
Article 
 
Ein Plädoyer für mehr Selbstvertrauen 
Date: 19/04/2010 
Medium: Der Standard (Online- und Print-Ausgabe) 
Article 
 
Mammographie-Screnning: Der Streit um den Nutzen geht in die nächste 
Runde 
Date: 16/04/2010 
Medium: Deutsches Ärzteblatt (Jg. 107, Heft 15, A698-700) 
Article 
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Warum Zahlen in der Medizin eine große Rolle spielen und warum nicht 
alles nur schwarz oder weiß ist 
Date: 04/2010 
Medium: NÖ PPA - Laut Gedacht 
Expertsletter(online) 
 
Erkrankt. Ermutigt. Entwürdigt. Neue Diskussionen über Pflicht, Ethik 
und Recht in der Medizin 
Date: 07/04/2010 
Medium: Ö1 - Salzburger Nachtstudio 
Radio review & announcement text 
 
Zahlenspiele in der Medizin 
Date: 03/2010 
Medium: Newsletter des Universitätslehrgangs Public Health, Graz 
 
Label gegen Off-label-Use: AMD Update 
Date: 29/03/2010 
Medium: ÖAZ 
Article 
 
Kontroverse Diskussion bei Buchpräsentation: Medizinische Zahlenspie-
lerei 
Date: 24.03.2010 
Medium: Medical Tribune (42. Jg, Nr. 12) 
Article 
 
Das Spiel mit den großen Zahlen 
Date: 16/03/2010 
Medium: Ärzte Woche 11/2010 (Online- und Print-Ausgabe) 
Article 
 
Bittere Pillen für Patienten 
Date: 12/03/2010 
Medium: Kleine Zeitung (Online- und Print-Ausgabe) 
Article 
 
Nicht nur auf die Kosten achten! 
Date: 12/03/2010 
Medium: Kronenzeitung (paid advertisement!) 
Advertisement 
 
Demokratisierung von Expertenwissen 
Date: 12/03/2010 
Medium: Medianet - health: economy 
Article 
 
Patienten sollten rechnen können 
Date: 11/03/2010 
Medium: Kurier (Online & Print-Ausgabe) 
Article 
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Neues Buch über Medizin und Kosten 
Date: 09/03/2010 
Medium: APA Journal Gesundheit 
Article 
 
Zahlenspiele in der Pharmaindustrie 
Date: 08/03/2010 
Medium: Ö1 Mittagsjournal 
Radio review & announcement text 
 
Zahlenspiele in der Medizin: Keine falschen Hoffnungen machen 
Date: 08/03/2010 
Medium: Der Standard (Online & Print-Ausgabe) 
Article 
 
Schlussbilanz: Nützen teure Behandlungen den Krebspatienten oder der 
Pharmaindustrie? 
Date: 08/02/2010 
Medium: Profil (Nr. 6) 
Article 
 
Krebstherapien: Qualitätsverlust 
Date: 05/02/2010 
Medium: Medianet - health: economy 
Article 
 
Neue Grippe: Für nichts gefürchtet oder Schwein gehabt? 
Date: 17/01/2010 
Medium: Die Presse am Sonntag 
Article 
 
Neue Grippe: Impfstoff günstig abzugeben 
Date: 10/01/2010 
Medium: Kurier am Sonntag 
Article 
 
Two media highlights in 2010 were the following live TV and radio broad-
casts:  
 Live TV political discussion „Im Zentrum“ (ORF 2)  on „Sick sys-
tem – Is health becoming unaffordable?“, Haas-Haus Vienna, 
21/11/2010 (Claudia Wild) 
 Interview about the LBI-HTA „Number games in medicine“ book 
presentation, Ö1 Mittagsjournal, 04/03/2010 (Claudia Wild and 
Brigitte Piso) 
The LBI-HTA press review 2010 is also available at: 
http://hta.lbg.ac.at/de/content.php?iMenuID=82 
Project leader/ Press contact: Gerda Hinterreiter  
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The LBI-HTA website - http://hta.lbg.ac.at - contains updated announce-
ments or presentations of publications and reports, research projects, events, 
press reviews, team profiles and other current news concerning the LBI-
HTA.  
According to the website statistics the Institute’s homepage and webpages 
had 1,533,849 hits in 2010 Comparing months shows that the fewest hits 
were received in December (69.295), and that January saw the highest num-
ber of hits (173.021). 
Projectleader/Webmaster: Gerda Hinterreiter  
Figure 2.1-2: Website hits 2008, 2009 & 2010 
 
Figure 2.1-3: Website visits  2008, 2009 & 2010 
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Procedures in evaluation – kyphoplasty and vertebroplasty 
Project leader: Brigitte Piso (since 2009) 
Duration: 2006 – 09/2010 
Background: Kyphoplasty (KP) and vertebroplasty (VP) are minimal invasive 
procedures for the treatment of painful osteoporotic vertebral compression 
fractures (VCFs). Evidence for the effectiveness of KP and VP under routine 
care conditions is low. Predictive factors for a clinically relevant outcome 
have not been identified yet.  
Aims & methods: Aim of the study was to identify predictive factors for the 
longterm success of both procedures. Additionally safety data (e.g. subse-
quent, adjacent fractures, cement leakages) were collected. Moreover it 
should be examined, if the interventions were able to reduce the kyphotic 
angle and if this reduction was related to clinical outcome parameters. A pro-
spective cohort study was chosen as study design. The expected sample size 
was not reached. Because of low data quality (sample at the beginning n = 
88, at the second medical examination n = 38 and heterogeneous observation 
periods) and between groupsdifferences in baseline characteristics we con-
ducted a descriptive analysis.  
Results: The groups (KP, VP) differed in baseline characteristics (e.g. spon-
taneous vs. traumatic fracture, osteoporosis, Oswestry Disability Index). We 
observed cement leakages in both groups, but none of them required further 
intervention. Oswestry Disability Index improved by an average of 50 points 
after KP and by 37 points after VP. Pain was reduced by 67 VAS points in 
the KP-group and 61 VAS points in the VP-group. The pain reduction and 
the improvement in the ODI score was sustained with minimal losses until 
the end of the observation period after two years.  
Discussion: This observational study shows that KP and VP were able to im-
prove functionality and to reduce pain under routine care conditions. Be-
cause of between group differences in baseline characteristics direct compari-
sion of outcomes was not feasible. Because of study limitations not all re-
search questions could be fully answered.  
Conclusion: Results of currently conducted randomised controlled trials 
should be followed. Patients should be included in registries and informed 
about expected benefits and harms prior to both interventions.  
Publication: HTA Project report 25 - http://eprints.hta.lbg.ac.at/900/ 
Outpatient Cardiac Rehabilitation –  
Part 3: Retrospective cohort study (with/without phase III rehabilitation) 
Project leader: Brigitte Piso  
Project team: Michael Gyimesi, Brigitte Piso, Heinz Tüchler 
Duration: 10/2008 – 04/2010 
Part 3a: Explorative analysis and developing of an evaluation plan 
Part 3b: Application of the evaluation plan 
Background: Cardiac rehabilitation is an essential therapeutic step in ensur-
ing patient reintegration into work-, social- and family life following acute 
cardiac incidents or cardiac surgical procedures. Phase I of the cardiac reha-
bilitation is conducted in inpatients in terms of early mobilisation after an 
acute incident. The phase II cardiac rehabilitation normally takes 4-6 weeks 
programme line  4 
programme line  4 
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and in many countries this is performed on an outpatient basis. In Austria 
only a small number of cardiac patients participate in outpatient rehabilita-
tion programs. However, the outpatient cardiac rehabilitation is assumed to 
be as effective and safe as inpatient rehabilitation care and in addition is 
more cost-effective. Phase III is always conducted on an outpatient basis and 
should support the sustainability of the rehabilitation. 
In 2008, the first two parts of this project (“outpatient cardiac rehabilita-
tion”) were finished. The objective, on the one hand, was to identify indica-
tors and methods which are suitable for the formative and summative evalua-
tion of outpatient cardiac rehabilitation, and on the other hand, to conduct a 
comparative analysis of various rehabilitation models of Phase II as well as an 
analysis of the efficacy of phase III interventions.  
Aims and research objectives: Because of the observed great heterogeneity of the 
programs in regard to the contents and models of rehabilitation we suggested 
the evaluation of Austrian phase III rehabilitation programs to prove their ef-
fectiveness. Therefore a retrospective cohort study based on clinical data 
from patients who attended cardiac rehabilitation centres and account data 
from health insurance institutions was planned. 
The first objective was the estimation of the effectiveness of outpatient car-
diac phase III rehabilitation. The second objective was to give decision guid-
ance for the Association of Austrian Health Insurance Providers for negotia-
tions concerning the prolongation of contacts between them and outpatient 
rehabilitation centers.  
Methods: In a first step we developed an evaluation concept based on the 
analysis of the centre for outpatient rehabilitation (ZAR) owned by the Pen-
sion Insurance institution (HTA Project report No. 31a). In a second step we 
applied the concept to the centers of the working group on outpatient cardiac 
prevention and rehabilitation (AGAKAR) - (HTA Project report No. 31b).  
Publications (Part 1, 2, 3a, 3b):  
HTA Project report 15 (Part 1+ 2/2008):http://eprints.hta.lbg.ac.at/800/ 
HTA Project report 31a (Part 3a/2010): http://eprints.hta.lbg.ac.at/875/ 
HTA Project report 31b (Part 3b/2010): http://eprints.hta.lbg.ac.at/876/ 
Outpatient cardiac rehabilitation -  
Part 4: Development of a study protocol for a prospective, controlled 
study to assess the effectiveness of phase III rehabilitation 
Project leader: Brigitte Piso 
Project team: Brigitte Piso, Heinz Tüchler 
Duration: 04/2010 – 06/2010 
Background: The current project is based on three already completed parts of 
the project “Outpatient cardiac rehabilitation”: The objective of the first 
parts was to identify indicators as well as appropriate methods or instru-
ments which are suitable for the formative and summative evaluation of out-
patient cardiac rehabilitation (HTA Project report No. 15). Further objec-
tives were to to conduct a comparative analysis of various rehabilitation 
models of phase II as well as an analysis of the efficacy of phase III interven-
tions (HTA Project report No. 31a and HTA Project report No. 31b). We ob-
served a great heterogeneity regarding the contents and models of rehabilita-
tion. Beyond that, the results of published phase III cardiac rehabilitation 
trials or international field reports could not be transferred to the national 
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health care system directly. Therefore we conducted a retrospective cohort 
study, based on clinical data from patients who attended cardiac rehabilita-
tion centres, and account data from health insurance institutions. Because of 
the non-randomised retrospective study design, which could not safeguard 
against systematic differences between groups, the limited data quality and 
the considerable proportion of missing data, the estimation of effectiveness of 
outpatient cardiac phase III rehabilitation was not feasible. A spin-off effect 
of the project was that it highlighted possibilities and pitfalls of evaluating 
routine data. These results will be used for planning a prospective study 
evaluating the effectiveness of cardiac rehabilitation. 
Objectives - Planning phase: Agreement between all partners on study objec-
tives (research questions, study design, endpoints…); Considerations con-
cerning feasibility (especially: data availability and quality) 
Objectives – Study: To assess the effectiveness of Austrian outpatient cardiac 
phase III rehabilitation; to provide decision-making guidance to the Associa-
tion of Austrian Health Insurance Providers for negotiations concerning the 
prolongation of contacts between them and outpatient rehabilitation centres 
of the working group on outpatient cardiac prevention and rehabilitation 
(AGAKAR) 
Methods: Development of the study protocol; Draft of the protocol, which 
outlines different options (e.g. different research questions, study endpoints) 
will be discussed (and finally approved) by a project group, consisting of 
LBI-HTA-members, members of the HVB and the pension insurance insti-
tution as well as the AGAKAR; Prospective study (starting in autumn 2010), 
study options to be discussed  
Horizon Scanning in Oncology – From pilot to routine 
Project leader: Anna Nachtnebel 
Project team: Anna Nachtnebel, Katharina Hintringer 
Duration: regularly from 10/2008  
Background: The first part of our project "Horizon Scanning in Oncology", 
which was carried out between July 2007 and May 2008 focused on the devel-
opment of a concept for a Horizon Scanning System in oncology and the test-
ing of two important steps (i.e., "identification" and "prioritisation") in the 
context of a short pilot. On the whole our initial experiences with the Hori-
zon Scanning System from the feasibility study were acceptable but several 
changes, especially regarding the collection of data on anticancer drugs and 
the priority setting process, were proposed by the experts involved. Based on 
these findings, an optimised final concept has been developed with various 
stakeholders (e.g. hospital administrators, clinical experts, drug commis-
sions). 
Aims and research objectives: Since the development of an optimised and final 
concept in automn 2009, the Horizon Scanning System has made standard 
practice at the LBI-HTA to regularly provide Austrian hospitals (hospital 
management and drug commissions) with information (assessments) about 
new/ emerging anticancer drugs to support their financial drug budget plan-
ning and rational decision making.  
Methods: Weekly scanning of information sources with data extraction, quar-
terly prioritization process through an interdisciplinary oncology team of ex-
perts, writing assessments for relevant cancer drugs under development 
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("emerging anti-cancer drugs), dissemination of these reports and the evalua-
tion of the Horizon Scanning Programme after a certain start-up phase.  
Members of the interdisciplinary oncology team of experts are: 
 Dr. Anna BUCSICS, Hauptverband der Österr. Sozialversicherung-
sträger, Department for Evidence Based Economic Healthcare, Vi-
enna; 
 Dr. Michael POBER, KH St. Pölten, Haematology and oncology, 
NÖ Landeskliniken Holding; 
 Dr. Johannes ANDEL, LKH Steyr, Oncology and Public Health, 
GESPAG, OÖ; 
 Mag. Andreas SEIRINGER, LKH Vöcklabruck, Deputy director of 
hospital pharmacy, pharmacist, GESPAG, OÖ; 
 Prim. Dr. Peter KRIPPL, LKH Fürstenfeld, Haematology and on-
cology, KAGES, Styria; 
 Dr. Wolfgang WILLENBACHER, LKH Innsbruck University 
hospital, Haematology and oncology, TILAK, Tyrol; 
Results: As these early assessments are promptly made available and are pub-
lished in English, they have aroused significant interest internationally, as 
well as in Austria. Due to apparent EU-wide overlaps, the considerable fi-
nancial implications and the increased demand for the evaluation of oncol-
ogy drugs, a two day „Workshop on Onco-drugs“ took place at the LBI-HTA 
at the end of September/beginning of October. 20 people from 12 European 
HTA Institutes took part, in order to - for the first time - develop options for 
future cooperation in the rapid evaluation of oncology drugs.  This workshop 
was proposed and hosted by the LBI-HTA, as the lead partner of the 
EUnetHTA Joint Action WP 7B. The joint publication of two Horizon Scan-
ing in Oncology Assessments with partner institutions (Universitätsklini-
kum Bremen and the Polish HTA institute AHTAPol; early January 2011) is 
one of the first outcomes of this successful get-together. 
Publications: 14 Decision Support Documents for Horizon Scanning in On-
cology have been published since autumn 2009, including 9 in 2010: 
 Gefitinib (Iressa®) for the first-line treatment of non-small cell lung 
cancer. DSD: Horizon Scanning in Oncology 06. 
http://eprints.hta.lbg.ac.at/868/ 
 Trabectedin (Yondelis®) for second-line recurrent platinum-
sensitive ovarian cancer. DSD: Horizon Scanning in Oncology 07. 
http://eprints.hta.lbg.ac.at/869/ 
 Plerixafor (Mozobil ®) for autologous stem cell transplantation in 
patients with lymphoma and multiple myeloma. DSD: Horizon 
Scanning in Oncology 08. http://eprints.hta.lbg.ac.at/878/ 
 Lapatinib (Tyverb®/Tykerb®) for the first-line therapy of ad-
vanced/metastatic breast cancer. DSD: Horizon Scanning in Oncol-
ogy 09. http://eprints.hta.lbg.ac.at/882/ 
 Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent 
non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia 
(CLL) and multiple myeloma. DSD: Horizon Scanning in Oncol-
ogy 10. http://eprints.hta.lbg.ac.at/884/ 
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 Panitumumab (Vectibix®) for the first-line treatment of metastatic 
colorectal cancer. DSD: Horizon Scanning in Oncology 11. 
http://eprints.hta.lbg.ac.at/880/ 
 Trastuzumab (Herceptin®) in addition to standard chemotherapy 
as first-line therapy for advanced gastric cancer. DSD: Horizon 
Scanning in Oncology 12. http://eprints.hta.lbg.ac.at/881/ 
 Pazopanib (Votrient®) for the treatment of locally advanced and/or 
metastatic renal cell carcinoma. DSD: Horizon Scanning in Oncol-
ogy 13. http://eprints.hta.lbg.ac.at/902/ 
 Ipilimumab for pretreated patients with advanced/metastatic mela-
noma. DSD: Horizon Scanning in Oncology 14.  
http://eprints.hta.lbg.ac.at/905/ 
All Decision Support Documents - Horizon Scanning Series in are available 
at: http://hta.lbg.ac.at/de/content.php?iMenuID=96  
IFEDH - Innovative Framework for Evidence Based Decision Mak-
ing in Health Care 
Project leader: Ingrid Zechmeister 
Project team: Philipp Radlberger 
Duration: 10/2010 – 03/2011 
Background: The extraordinarily high amount of 20-25 billion Euros of an-
nual turnover in the Austrian health system has increasingly raised the ques-
tions of cost-effectiveness and evidence based decision making in health care. 
Health technology assessment is already intensively dealing with these is-
sues, especially on the level of single interventions. Nonethelss, due to a lack 
of data, assessments often include modelling or simulation techniques in or-
der to analyse long-term effects. This, in turn requires the increasing coop-
eration of experts from different fields of science such as HTA, statistics, data 
management, modelling & simulation as well as visualisation. A common 
understanding on contents, methodology and terminology needs to be devel-
oped. In Austria, such a common understanding has yet to be developed in a 
systematic way so far.  
Aims of project: The main aim of the IFEDH project is to support evidence 
based decision making in health care using a tool which helps to make the 
most of the potential of HTA, modelling, simulation, statistics and data 
analysis.Therefore, common standards will be defined in order to facilitate 
cooperation and interdisciplinary work. Three practical examples will be 
used to test the applicability of the tool.  
LBI-HTA took the leading role in work package 1 (WP1) as well as the exe-
cution of WP1.2 and WP2.1. Both WPs will address state of the art standards 
in HTA. WP1.2 focuses on quality standards in the discipline in general and 
on the evaluation of vaccination programmes in particular. The aim is to 
publish an English review. WP2.1 describes the terminology of simulation 
and modelling in the specific context of HTA. The aim is to create a glossary 
in English and German, taking into consideration the most relevant interna-
tional sources. 
Research objectives WP1.2: What are general principles of standardised work 
in HTA? Which standards exist to examine data validity in primary studies? 
Which standards exist to examine data validity in systematic reviews? Which 
standards exist to examine economic studies? Which standards exist in 
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HTA-manuals to examine modelling? Which standards explicitly refer to 
evaluating vaccination programmes? What are the limitations that HTA is 
subject to, regardless of quality standards? 
Research objectives WP2.1: According to HTA criteria, what are the German 
and English linguistic standards in matters of definitions and terminology in 
modelling and simulation? 
Methods WP1.2 & WP2.1: Hand search based on methodological manuals of 
leading international institutions as well as hand search in other relevant lit-
erature. WP1.2: Description of sources, list of standards and critical synthe-
sis of results in English language; WP2.1: Table of identified terms in the 
form of a glossary. 
EUnetHTA Joint Action 2010-2012 
Project leader: Claudia Wild 
Project team: Claudia Wild, Gerda Hinterreiter, Marisa Warmuth, Stefan Mathis, 
Anna Nachtnebel 
Duration: 2006-2008; 2009; 2010-2012;  
Background: In the course of termination of the EU-project EUnetHTA 2006-
2008 the partner organisations aimed to develop a strategic concept in order 
to ensure the continuation of EUnetHTA in the interim period of 2009. 
Overall, a group of 25 partner organisations, so-called “founding partners”, 
from 13 EU member states (+ Norway and Switzerland) actively worked on 
the sustainability of this project. The LBI-HTA was a “founding partner”of 
the EUnetHTA Collaboration in 2009. Following the interim period, this co-
operative scheme has now, thanks to long-term funding from the EU, devel-
oped into the „Joint Action 2010-2012“.  
Aims und Methods: In this Joint Action, the LBI-HTA is leading Work pack-
age 7B, with the aim of reducing overlaps in EU-wide HTA work. In 2010 to 
2012 WP 7/B will develop a webbased database containing all ongoing and 
planned assessemnts of the EUnetHTA Joint Action partner organisations in 
order to avoid overlaps in HTA-work across the EU. A web-based database of 
all Planned and Ongoing Projects (POP database) is to be made available to 
all EUnetHTA partner organisations.   
Results: Since January 2010 the LBI-HTA has been collecting planned and 
ongoing projects every three months. These projects are sorted according to 
topic and are made available to partners. The web-based POP database is cur-
rently being developed in cooperation with the Belgian HTA Institute KCE. 
It will be completed in summer 2011 and subsequently made available to all 
contributing (content providing) EUnetHTA partners.  
There has been further cooperation with other EUnetHTA partner organisa-
tions, such as during the LBI-HTA „Horizon Scanning in Oncology“ pro-
ject. Further cooperation, for example in the 2011 MEL assessments, is 
planned (in progress).   
Publications: available at EUnetHTA website -http://www.eunethta.eu 
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Piso, P., Abuzahra, M. (2010): Neuro- und Traumarehabilitation. Skalen 
und Scores zur Schweregraddifferenzierung. HTA-Newsletter March 2010, 
85:2. 
Piso, B. (2010): Koronare Herzkrankheit. Nichtmedikamentöse Sekundär-
prävention. HTA-Newsletter February 2010, 84:2. 
Radlberger, P. (2010): Opportunitätskosten neuer Technologien im Spitals-
bereich. HTA-Newsletter September 2010, 90:4. 
Radlberger, P. (2010): Kolonkrebs-Screening. Gesundheitsökonomische 
Evaluationen und Kostenentwicklun. HTA-Newsletter April 2010, 86:4. 
Schumacher, I. (2010): Memantin bei Alzheimer Demenz. HTA-Newsletter 
December 2010, 93:2. 
Schumacher, I. (2010): Spezifische Immuntherapie: Zur Behandlung der al-
lergischen Rhinitis. HTA-Newsletter July/ August 2010, 89:2. 
Schumacher, I. (2010): Qualitätsberichte in Krankenanstalten: Qualitätssi-
cherung durch Sicherheitskultur. HTA-Newsletter February 2010, 84:3. 
Warmuth, M. (2010): Assistierte Reproduktive Technologien: Ökonomische 
Analyse. HTA-Newsletter November 2010, 92:2. 
Warmuth, M. (2010): Octaplas® versus gefrorenes Frischplasma: Ökonomi-
sche Analyse. HTA-Newsletter July/ August 2010, 89:4. 
Warmuth, M. (2010): Hochintensiver Fokussierter Ultraschall (HIFU) bei 
Prostatakrebs. HTA-Newsletter June 2010, 88:2. 
Warmuth, M. (2010):  Forensische Psychiatrie: Evaluation von Endpunkten. 
HTA-Newsletter Mai 2010, 87:2. 
Warmuth, M. (2010): Hämocomplettan® P & Fibrogammin® P: Substituti-
on von Faktorenkonzentraten. HTA-Newsletter February 2010, 84:4. 
Winkler, R. (2010): Anorexia nervosa bei Jugendlichen: Versorgungseinrich-
tungen im Vergleich. HTA-Newsletter May 2010, 87:4. 
Winkler, R. (2010): Homöopathie im Spannungsfeld. HTA-Newsletter April 
2010, 86:2. 
Wild, C. (2010): Avastin® bei altersbedingter Makuladegeneration/ AMD. 
HTA-Newsletter November 2010, 92:2. 
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Wild, C. (2010): Frühbewertung neuer (innovativer) Arzneimittel: Neue 
Entwicklungen in Deutschland und engere Kooperationen in Europa. (Edi-
torial) HTA-Newsletter September 2010, 90:1. 
Wild, C. (2010): Burnout-Syndrom: Differentialdiagnostik. HTA-Newsletter 
July/ August 2010, 89:2. 
Wild, C. (2010): Bewertung Medizinischer Leistungen in/für Krankenanstal-
ten: Mengengerüste, methodische Routine und neue Herausforderungen. 
(Editorial) HTA-Newsletter June 2010, 88:1. 
Wild, C. (2010): Radiopeptidtherapie: Behandlung inoperabler, neuroendo-
kriner Tumore. HTA-Newsletter June 2010, 88:3. 
Wild, C., Hinterreiter, G. (2010): Europäisches HTA: Furcht oder Freude? 
Die enge Zusammenarbeit europäischer HTA-Institute trägt zunehmends 
Früchte. (Editorial) HTA-Newsletter May 2010, 87:1. 
Wild, C. (2010): Erythropoietin/EPO: Rise & Fall, Hype & Ernüchterung – 
Können oder wollen wir aus Fehlern lernen? (Editorial) HTA-Newsletter 
April 2010, 86:1. 
Zechmeister, I. (2010): Fehlervermeidung in entscheidungsanalytischen 
Modellen. HTA-Newsletter Oktober 2010, 91:3. 
Zechmeister, I. (2010): Bandscheibenprothesen. HTA-Newsletter June 2010, 
88:4. 
2.3 Participation in Scientific Meetings 
February: 
 Armutskonferenz, Salzburg, 22.-23/02/2010 (Roman Winkler) 
 12. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Me-
dizin: EbM- Ein Gewinn für die Arzt-Patient-Beziehung?; Salzburg, 
25.-27.02.2010 (Ines Schumacher, Marisa Warmuth, Gerda Hinterrei-
ter, Anna Nachtnebel, Claudia Wild, Katharina Hintringer, Roman 
Winkler, Tim Johansson, Ingrid Zechmeister, Stefan Mathis, Philipp 
Radlberger) 
 Kongress Integrierte Versorgung: Wunsch und Wirklichkeit, FH 
OÖ Linz, 25.-26/02/2010 (Brigitte Piso) 
 27. Jahrestagung der Österr. Gesellschaft für Kinder- und Jugend-
psychiatrie; Klagenfurt, 26.-27/02/2010 (Roman Winkler, Philipp 
Radlberger) 
March: 
 Symposium HPV-Prävention in Österreich: Sinn oder Unsinn? 
Billrothhaus Vienna, 01/03/2010 (Brigitte Piso, Claudia Wild, Ingrid 
Zechmeister) 
 Hospital Management Symposium, Austria Center Vienna, 
06/03/2010 (Claudia Wild) 
 Buchpräsentation „Zahlenspiele in der Medizin“, Presseklub Con-
cordia, Vienna, 09/03/2010 (everyone) 
 BBG/ Bundesbeschaffung Infotag, Wien, 15.03.2010 (Claudia Wild) 
99 participations at 
43 congresses and 
conferences 
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 10. Symposium Health Technology Assessment – Bewertung ge-
sundheitsrelevanter Verfahren. „Alles nicht ohne Evidenz?”, Ko-
logne, 18.-19/03/2010 (Katharina Hintringer) 
April: 
 Working Conference Health Services Research in Europe: Where 
research and policy meet, The Hague, The Netherlands, 08.-
09/04/2010 (Brigitte Piso, Stefan Mathis, Philipp Radlberger, Roman 
Winkler) 
 Deloitte Business Lunch, Vienna, 12/04/2010 (Claudia Wild) 
 Oncology Market Access Europe 2010, London, 13.-14/04/2010 
(Claudia Wild, Anna Nachtnebel) 
 Der Wiener Kontrollamtbericht, Podiumsdiskussion, Vienna, 
14/04/2010 (Claudia Wild) 
 18. Jahrestagung der Biomedizinischen AnalytikerInnen, FH 
Campus Vienna, 16.-17/04/2010 (Brigitte Piso) 
 Kindergesundheitsdialog, Bundesministerium für Gesundheit, 
Vienna, 28/04/2010 (Roman Winkler) 
May: 
 1. Österreichisches HTA-Symposium, Bundesministerium für Ge-
sundheit, Vienna, 03/05/2010 (Marisa Warmuth, Claudia Wild, Phi-
lipp Radlberger, Stefan Mathis, Ines Schumacher) 
 EURORDIS, Krakau, 04/05/2010 (Claudia Wild) 
 Diskussion „Medizinische Erkenntnisse – erforscht oder erkauft? 
-Wie frei ist die medizinische Wissenschaft? Auf dem Holzweg in 
die Sackgasse“; Österreichischer Hausärzteverband, Radiokultur-
haus Vienna, 11/05/2010 (Claudia Wild) 
 Versammlung österreichischer Mitglieder des Deutschen Netz-
werks Evidenzbasierte Medizin. Vienna, 21/05/2010 (Stefan Mathis) 
 13th Biennial SMDM European Meeting 2010 “Public Health De-
cision Making”. Society for Medical Decision Making, UMIT/ Hall 
i.T., 30/05.-02/06/2010 (Katharina Hintringer, Sabine Geiger-
Gritsch) 
June: 
 HTAi Conference, 7th Annual Meeting, Dublin, 06.-09/06/2010 
(Ines Schumacher, Marisa Warmuth, Gerda Hinterreiter, Anna 
Nachtnebel, Claudia Wild, Tarquin Mittermayr, Katharina Hintrin-
ger, Roman Winkler, Brigitte Piso, Ingrid Zechmeister, Philipp 
Radlberger, Stefan Mathis, Smiljana Blagojevic) 
 INAHTA Annual Meeting, Dublin, 09.-11/06/2010 (Claudia Wild)  
 (Un)gleich? Gesundheitsförderung und Prävention– Tagung, 
Linz, 10/06/2010 (Roman Winkler) 
 Kongress des Europäischen Forums für evidenzbasierte Präventi-
on (EUFEP), „Globale Evidenz für lokale Entscheidungen. Förde-
rung mentaler Gesundheit – Prävention psychischer Erkrankung“, 
Baden near Vienna, 16.-18/06/2010 (Roman Winkler, Ingrid Zech-
meister, Philipp Radlberger) 
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July: 
 Verband der forschenden Pharma-Unternehmen/ vfa - Symposi-
um "Umsetzung der frühen Nutzenbewertung in Deutschland", Ber-
lin, 07/07/2010 (Claudia Wild) auch am Podium/Diskussion 
August: 
 Europäisches Forum Alpbach 2010 – Gesundheitsgespräche “Ent-
wurf und Wirklichkeit, 20.-23/08/2010 (Claudia Wild) 
September: 
 13. Wissenschaftliche Tagung der Österreichischen Gesellschaft 
für Public Health „Lernen für Gesundheit“. JKU Linz, 16.-
17/09/2010 (Ines Schumacher, Gerda Hinterreiter, Anna Nachtnebel, 
Katharina Hintringer, Claudia Wild, Brigitte Piso, Roman Winkler) 
October: 
 1.nationale Konferenz für differenziertes Impfen, Wuppertal, 
Germany, 01/10/2010 (Brigitte Piso, Ingrid Zechmeister) 
 9.Deutscher Versorgungsforschungskongress, Bonn, 02/10/2010 
(Claudia Wild) 
 Jahrestagung der deutschen, österreichischen und schweizeri-
schen Gesellschaften für Hämatologie und Onkologie, Berlin, 01.-
05/10/2010 (Claudia Wild, Anna Nachtnebel)  
 13. European Health Forum Gastein/ EHFG, 05.-09/10/2010 (Phi-
lipp Radlberger) 
 HTA Workshop, KCE/ Belgian Health Care Knowledge Center, 
Brussels, 13.-14/10/2010 (Claudia Wild) 
 IIR-Tagung zu HTA & Pharmaökonomie, VIenna, 18.-19/10/2010 
(Claudia Wild) 
November: 
 Tagung „Leitlinien – Pro & Kontra“, Hauptverband der Sozialver-
sicherungsträger, Vienna, 03/11/2010 (Claudia Wild) 
 9. Int. Symposium Qualität im Gesundheitswesen „Zwischen den 
Zahlen: Daten – Fakten – Strategien“, Vienna, 04/11/2010 (Claudia 
Wild) 
 21. Jahrestagung der AG Urogynäkologie, Steyr, 05/11/2010 (Clau-
dia Wild)  
 SciCom Tagung - Berechtigte Information oder mediale Inszenie-
rung? Risikokommunikation im Spannungsfeld der Interessen, TU 
Vienna, 10/11/2010 (Brigitte Piso) 
 3rd European Public Health Conference, Amsterdam, The Nether-
lands, 11.-13/11/2010 (Brigitte Piso) 
 Beigewum Diskussionsforum „Welches Wissen braucht die Kri-
se?“, Vienna, 12/11/2010 (Claudia Wild) 
 Forum Alpbach Symposium „Medizin und Ethik: Wo steht der 
Mensch?“, Vienna, 17.-18/11/2010 (Claudia Wild) 
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December: 
 Health Care Rationing Conference, 09.-10.12.2010, Rotterdam, The 
Netherlands, (Anna Nachtnebel) 
 Eröffnung der Österreichischen Cochrane Zweigstelle, Krems, 
14/12/2010 (Claudia Wild, Ingrid Zechmeister) 
 Mitgliederversammlung der Arzneimittelkommission der deut-
schen Ärzteschaft, Berlin, 17/12/2010 (Claudia Wild) 
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3 Scientific Co-operations 
EUnetHTA JA, WP1 face-to-face meeting, Copenhagen/Denmark, 25.-
26/02/2010 (Claudia Wild) 
EUnetHTA JA, WP4 face-to-face meeting, Helsinki/Finland, 18/03/2010 
(Stefan Mathis) 
EUnetHTA JA, WP6 face-to-face meeting, Paris/France, 15.-16/04/2010 
(Gerda Hinterreiter, Marisa Warmuth) 
EUnetHTA JA, Plenary Assembly face-to-face meeting, Ljubljana/Slovenia, 
20.-21/05/2010 (Claudia Wild) 
EUnetHTA JA, WP7 face-to-face meeting, Dublin/Ireland, 10/06/2010 
(Claudia Wild, Gerda Hinterreiter, Marisa Warmuth) 
EUnetHTA JA WP7B & WP5 Onco drugs Workshop, LBI-HTA Vienna, 
30/09.-01/10/2010 (Claudia Wild, Anna Nachtnebel, Katharina Hintringer) 
EUnetHTA JA, WP6 face-to-face meeting, Brussels/Belgium, 12.-13/10/2010 
(Gerda Hinterreiter) 
EUnetHTA JA, WP1 & Executive Committee face-to-face meeting, Brus-
sels/Belgium, 14.-15/10/2010 (Claudia Wild) 
EUnetHTA JA, WP4 face-to-face meeting, Rome/Italy, 25/11/2010 (Stefan 
Mathis) 
EUnetHTA JA WP1 & Executive Committee e-meeting, 03/02/2010, 13:00–
14:30 (Gerda Hinterreiter, Marisa Warmuth) 
EUnetHTA JA WP6/A & WP7/B e-meeting, Training for Workroom admin-
istrators, 11/03/2010, 12:00-13:00 (Gerda Hinterreiter) 
EUnetHTA JA WP1 & Executive Committee e-meeting, 07/04/2010, 13:00–
14:30 (Claudia Wild, Gerda Hinterreiter) 
EUnetHTA JA WP1 & Executive Committee e-meeting, 05/05/2010, 13:00–
14:30 (Claudia Wild, Gerda Hinterreiter) 
EUnetHTA JA WP1 & Executive Committee e-meeting, 30/06/2010, 13:00–
15:00 (Gerda Hinterreiter) 
EUnetHTA JA WP1 & Executive Committee e-meeting, 07/07/2010, 13:00–
14:00 (Gerda Hinterreiter) 
EUnetHTA JA WP1 & Executive Committee e-meeting, 08/09/2010, 13:00–
15:00 (Gerda Hinterreiter) 
EUnetHTA JA WP6 & WP7/B e-meeting, POP database preparation, 
22/09/2010, 11:00–12:30 (Claudia Wild, Gerda Hinterreiter) 
EUnetHTA JA WP1 & Executive Committee e-meeting, 09/12/2010, 13:00–
15:00 (Claudia Wild, Gerda Hinterreiter) 
EuroScan meeting, Verona/Italy, 29.-30/03/2010 (Anna Nachtnebel) 
EuroScan meeting, Dublin/Ireland, 06/06/2010 (Katharina Hintringer 
representing Anna Nachtnebel) 
EuroScan meeting, Cologne/Germany; 02.-03/12/2010 (Anna Nachtnebel) 
9 EUnetHTA  
face-to-face meetings  
9 EUnetHTA  
e-meetings 
3 EuroScan meetings 
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INAHTA-annual meeting, Dublin/Ireland, 09-11/06/2010 (Claudia Wild)  
EUROCHIP/ European Cancer Health Indicator Project meeting, WP7 on 
Cancer Costs and Outcomes, Rome/Italy, 03/05/2010 (Anna Nachtnebel) 
Networking event of the Austrian HTA-institutes (LBI-HTA, UMIT-IPH, 
DUK, BIQG und EBM-Center Graz) in Melk/NÖ, 27.-28/09/2010 (Philipp 
Radlberger, Stefan Mathis, Katharina Hintringer) 
UMIT – Health and Life Sciences University, Hall in Tirol: Planning and 
delivery of a 6-day training course: „Winter School in Clinical Epidemiol-
ogy“, 24.-29/01/2011 
DUK – Danube University Krems, Department for Evidence-based Medi-
cine and Clinical Epidemiology: Planning and delivery of a joint 5-day work-
shop: „Health Technology Assessment“, 05.-10/10/2010  
Think Tank Workshop as part of the Parents-Child-Prevention project with 
13 national experts at the LBI-HTA Vienna, 23/06/2010 (Brigitte Piso, Ma-
risa Warmuth, Roman Winkler, Ingrid Zechmeister, Claudia Wild) 
In the context of the „Horizon Scanning in Oncology“ project Anna Nacht-
nebel and Katharina Hintringer worked with the following experts in the 
field of Oncology/Pharmacy:  
 Dr. Anna BUCSICS, Hauptverband der Österr. Sozialversicherung-
sträger, Department for Evidence Based Economic Healthcare, Vi-
enna; 
 Dr. Michael POBER, KH St. Pölten, Haematology and oncology, 
NÖ Landeskliniken Holding; 
 Dr. Johannes ANDEL, LKH Steyr, Oncology and Public Health, 
GESPAG, OÖ; 
 Mag. Andreas SEIRINGER, LKH Vöcklabruck, Deputy director of 
hospital pharmacy, pharmacist, GESPAG, OÖ; 
 Prim. Dr. Peter KRIPPL, LKH Fürstenfeld, Haematology and on-
cology, KAGES, Styria; 
 Dr. Wolfgang WILLENBACHER, LKH Innsbruck University 
hospital, Haematology and oncology, TILAK, Tyrol; 
Consultations and interviews at the Department for Addiction at the Wag-
ner-Jauregg Nervenklinik Linz (AfA) and the Anton Proksch Institut 
Kalksburg (API) as part of the „Economic aspects of clinically effective 
and efficient models of health services in alcohol addiction treatment 
III” project  (Philipp Radlberger) 
Prim. Univ. Prof. Dr. Leonhard Thun-Hohenstein, Board of directors of the 
University Clinic for Child and Youth Psychiatry at the Christian-Doppler-
Klinik Salzburg as part of the „Child and youth psychiatry Salzburg“ evalua-
tion project (Roman Winkler) 
 
1 INAHTA meeting 
1 EUROCHIP meeting 
national cooperations  
Scientific Co-operations 
LBI-HTA | 2011 77 
Evaluation team meeting at the University Clinic for Child and Youth Psy-
chiatry, Christian-Doppler-Klinik; Salzburg, 05/02/2010; 25/03/12010; 12.-
14/07/2010 and 07.-11/10/2010 (Roman Winkler) 
Project collaboration with wire products shop (“Drahtwahrenhandlung”), 
Association of Social Security (“Hauptverband der österr. Sozialversi-
cherungsträger”), Technical University Vienna, VRVis Centre for Virtual 
Reality and Visualisation Research-GmbH, FDW GmbH, Florian Endel, 
and Executive Information Service GmbH, as part of the „IFEDH/ Innova-
tive Framework for Evidence Based Decisionmaking in Healthcare“ project 
(Ingrid Zechmeister, Philipp Radlberger, Claudia Wild) 
During the development of the „National HTA Strategy“ and the joint 
„Methodological Handbook for HTA“ the LBI-HTA collaborated with 
GÖG/ Gesundheit Österreich. 
MEL/NUB collaboration with the Medical Service of the Alliance of Health 
Insurers (MDS), Dr. Annette Busley, Deutschland (Claudia Wild)  
Expert workshop as part of the Impact project at the LBI-HTA 
(08/03/2010; 11:00-16:00) with invited scientists from Germany and Austria:  
 Ansgar Gerhardus, Evelyn Dorendorf - Universität Bielefeld 
 Petra Schnell-Inderst, Ruth Schwarzer, apologies: Uwe Siebert - 
UMIT: 
 Britta Göhlen - DIMDI 
 Claudia Wild, Ines Schumacher, Ingrid Zechmeister – LBI-HTA 
EUnetHTA WP 7B & WP 5 “Workshop on Onco-drugs“, LBI-HTA as host 
and initiator. Vienna, 30/09.-01/10/2010 (Claudia Wild, Katharina Hintrin-
ger, Anna Nachtnebel) 
ZeS/ Centre for Social Policy, Departments for Health Economics, Health 
Policy and Health Care Research (Rothgang, Schmacke, Gläske) – Lecture on 
HTA as a tool for developing statutory health insurance (Claudia Wild) 
EU COST-Network „Childbirth Cultures, Concerns, and Consequences: 
Creating a dynamic EU framework for optimal maternity care” (Roman 
Winkler) 
AOK Germany: Update of online HPV decision aid (www.hpv-
entscheidungshilfe.de) in April 2010 (Brigitte Piso) 
IQWIG/ Department for pharmaceutical evaluation (D. Kaiser): Consulta-
tion on  comments procedure (Claudia Wild) 
EMKI/: Austrian-Hungarian collaboration in the evaluation of medical 
technologies (Claudia Wild) 
Co-author – German memorandum register for health care research, German 
Health Care Research, Lead: Edmund Neugebauer, Institute for Operative 
Medicine, Köln (Stefan Mathis) 
Co-author „Diabetes Mellitus Registry Studies“, Dirk Müller, Institute for 
Health Economics and Clinical Epidemiology (IGKE) University Clinic 
Köln (Stefan Mathis) 
further international 
collaboration 
collaboration as part of 
publication projects 
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In 2010 the following external authors provided editorials for the HTA-
Newsletter:  
 Dipl-Ing. Berthold Reichardt, Burgenland regional health insur-
ance. „The treatment of rheumatoid arthritis in Austria – Myths 
and reality“ (HTA-Newsletter 84:1) 
 Dr. Angela Kaminiski, Director of the EBM Information Centre, 
Department for evidence based medicine and clinical epidemiology, 
Danube University Krems. „EBM for lower Austrian hospital doc-
tors: the benefit of missing evidence“ (HTA Newsletter 85:1) 
 Dipl.-Soz. Sabine Stumpf, Institute for Social Medicine, Luebeck 
University. „What is important to citizens? First citizens’ confer-
ence on prioritisation in health care“ (HTA Newsletter 80:1) 
 Dr. Peter Mrak, Chairman of the Society for Quality in Geriatrics 
and Gerontology (QIGG). „Benchmarking projekt: acute geriat-
rics/remobilisation in Austria: the successful transfer of published 
findings to treatment reality“ (HTA Newsletter 91:1) 
 Dr. Christian Euler, President of the Austrian General Pratitioners’ 
Asociation. „Testosterone deficiency (in ageing men) – the ‘Climac-
terium virile’: a prime example of disease mongering” (HTA News-
letter 92:1) 
 Univ.-Prof. Dr. Barbara Maier, Director of the Clinic for Gynaeco-
logical Endocrinology and Assisted Reproduction at the University 
Clinic for Gynaecology and Obstetrics, Salzburg „Successes in re-
productive medicine? A number game“ (HTA Newsletter 93:1) 
 
further collaboration 
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4 Other Activities 
In 2010 Claudia Wild taught 
 On the „Health care management“ Masters course at the „FH-
Kärnten (13.-15/01/2010),  
 On the „Public Health and Health Systems Management“ Masters 
course at the Kepler Universität Linz (15/02/2010), 
 On the „Public Health“ Masters course at the Medical University 
Graz, Location Schlosshofen (18.-19/03/2010), 
 On the „Public Health“ Masters course at the Medical University 
Graz, Location Vienna (09/04/2010), 
 On the „Gesundheitswissenschaften“ Masters course at UMIT in 
Hall in Tyrol (21/04/2010)  
 On the „E-Health“ Masters course at the FH-Joanneum (in collabo-
ration with Joanneum Research), Graz (20.-21/12/2010). 
Ingrid Zechmeister is a visting lecturer 
 On the „Public Health“ Masters course at the Medical University of 
Graz. She gave lectures on „Health Economic Evaluation“ on 
19/03/2010 in Dornbirn and on 10/04/2010 in Vienna, 
 On the „Biomedical analysis“ Bachelors course at the FH-Campus 
Wien, in the course of which she taught on the „Health care and 
health economics“ module from 15.-22/02/2010  
 On the „Biomedical analysis“ Masters course at the FH-Campus 
Wien. She taught on the „Health economics module“ 11.-12/06/2010  
 In the field of „Health Economic Evaluation“ (Danube University 
Krems on 26/11/2010). 
Brigitte Piso taught at the Danube University Krems  
 On the Masters course in Advanced Orthopedic Surgery, giving a 
lecture on „Public Health, Epidemiology, EBM“ on 20/03/2010 
 and during the Workshop on Health Technology Assessment, giving 
a lecture on „HTA & gesundheitspolitische Entscheidungen“ on 
22/11/2010. 
Tarquin Mittermayr taught „Literature searching with Embase and Ovid-
Medline“ as part of the 2-day „Systematic literature search“ workshop at the 
Department for evidence based medicine and clinical epidemiology at the 
Danube University Krems (11.-12/05/2010) 
Roman Winkler was a vistiting lecturer at the Promente-Akademie, Vienna, 
Focus: Research and scientific methodology, as part of the „Psychotherapeu-
tic preparatory course“ on 14.-16/05/2010, 28.-30/05/2010 and 11.-12/06/2010. 
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In 2010 Claudia Wild reviewed manuscripts for the following journals: 
 “German Journal for Evidence and Quality in Healthcare“ (ZEFQ) 
 BMC Health Services Research 
 European Journal of Public Health  
 Health Policy 
 Croatian Medical Journal  
 Pharmaceutical Medicine 
 NL-ZonMW Review Pharmacotherapie 
Ingrid Zechmeister was engaged in reviewing for the: 
  Journal of Public Health,  
 The Netherlands Organisation for Health Research and Develop-
ment,  
 Ireland Health Research Board  
 5. Forschungsforum der österreichischen Fachhochschulen  
In July 2010 Brigitte Piso reviewed the Pensions Insurance Institute‘s study 
protocol on „The sustainability of cardiac rehabilitation“. 
The following diploma- and master theses were supervised by senior re-
searchers, and supported by library services in 2010: 
 Mag. Harald Keckeis (Public Health Masters course/ Health Care 
Sciences at the University of Graz): „HTA as a Controlling Instru-
ment“ - Claudia Wild  
 Dr. med Thomas Dorner MPH (Postdoctoral studies at the Medical 
University of Graz/Social Medicine) Review of “Social determinants 
of health resources, health behaviour and morbidity, and conse-
quences for social medicine and Public Health” -  Claudia Wild  
 Muna Abuzahra, BA (FH Kärnten, Health and care): „Measure-
ment of Severity in Neurorehabilitation – International experiences 
and status quo in Austria“ - Brigitte Piso 
Ongoing supervision of Masters theses:  
 Mag. Philipp Radlberger (WU Wien, Doctoral studies in economic 
policy): Economic analysis in the field of psychiatric indications – 
Possibilities and problems with health economic methods, illus-
trated by the examples of child and youth psychiatry and alcohol 
therapy – Review of research proposal - Claudia Wild 
 
expert & referee 
activities 
supervision of diploma 
and doctoral theses 
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5 Outlook 
In 2004 the Ludwig Boltzmann Society (LBG) laid out plans for the creation 
of new Institutes. It decided that the „new“ LB Institutes would exist for a 
period of 7 years, under the umbrella of its academic  but non-university-
based research institution, in order to, within that time period, demonstrate 
their benefit to translational research to the society’s partners.  
Now, the LBG has offered those Institutes which have shown themselves to 
be successful in their first 4 years the option of a second period, on the fol-
lowing conditions.  
Co-financing beyond 2013 requires:  
1. The handover of the Institute to an alternative legal representative, 
as well as the withdrawal of LBG funding during the second period  
2. The handover must be pre-arranged; the approach to the timely 
withdrawal of the LBG is negotiable. The total sum made available 
by the LBG is non-negotiable.  
3. Albeit that the legal representative may/ought to be – despite the co-
financing of the LBG – another organisation, the LBG logo should 
continue to be used throughout the co-financing period.   
4. Before initial negotiations can begin, „Letters of Intentions“ from 
the new legal representative must be presented.  
Thus the LBI-HTA is preparing for a second period (2013-2020) – it has car-
ried out an impact analysis of HTA (HTA-project report 37ab: Impacts of 
HTA research on health care in Austria) as well as a broader study about the 
need for knowledge in modern health care systems (HTA-project report 48: 
Knowledge base for a better health care system in Austria: Approaches to 
Capacity Building in Health care and public health research from other 
countries). In addition to this, it has developed a strategy paper (unpub-
lished: December 2010) detailing possible new areas of research. All these 
documents provide a basis for negotiations.  
Aside from these long-term plans, there are two birthdays to be celebrated in 
2011: The 5 year anniversary of the LBI-HTA (May 2011) and the 10 year 
anniversary (and the 100th edition) of the HTA Newsletter (September 2011). 
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